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Abstract
The syndrome of falls is a common and serious problem and if we are considering the older pop-
ulation this problems takes even greater proportions. Falls can today be associated with multiple
causes, which are related with factors that can be hard to track. In order to prevent side effects,
among them falls, from happening medications usually lists possible unwanted symptoms. How-
ever, when a patient is using multiple drugs side effects may happen due to the combination of
medicine.
In order to identify combinations and single pharmacological drugs that may have some side
effects related to falls, new community based solutions must be developed. In this project we
developed a system capable of analysing and evaluating the fall risks associated with medical
drugs usage on the elders. This system must be capable of making this evaluation regarding a
single drug or a drug combination, pointing out the riskier drugs or combinations.
We used a process that classifies the drugs according to their classes, types or families and
assess if that classification represents a group or a specific substance of risk to this scenario. The
system was capable of making the evaluation within reasonable time and provide the analysis
conclusion to the user. The system achieved the expected results with a success ratio of 90% for
single drug evaluations in a test with 93 drugs and 70% for drug-drug interactions in the conducted
tests, the system has proven to achieve the expected results.
i
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Resumo
A ocorrência de quedas é um problema sério e comum nos dias de hoje. Se considerarmos uni-
camente a população mais idosa este problema toma proporções ainda mais alarmantes. O acon-
tecimento de quedas está actualmente associado a várias causas que estão ligadas a factores que
podem ser dificeis de determinar. Para prevenir consequências relativas aos efeitos secundários, a
medicação actualmente contem um panfeto que lista os possiveis efeitos adversos das substâncias
a tomar. No entanto, quando um paciente utiliza múltiplos medicamentos podem surgir efeitos
secundário adversos provenientes dessas combinações farmacológica.
De forma a identificar combinações medicamentosas e medicamentos unicos que possam ter
efeitos secundários relacionados com quedas, novas soluções e estudos baseados em comunidades
tem de ser desenvolvidos. Neste projeto temos como objectivo desenvolver um sistema capaz de
analisar e avaliar o risco de queda associado ao consumo de medicamentos nos idosos. O sistema
deve ser capaz de analisar a utilização de medicamentos separadamente e em conjunto, tendo a
capacidade de detectar efeitos provenientes das combinações.
Durante o desenvolvimento do projeto utilizamos critérios que classificam os medicamentos
de acordo com a sua classe/tipo/familía e a partir desta informação verifica se esse medicamento
faz parte de um grupo potencialmente perigoso. O sistema final revelou em testes ser capaz de
avaliar correctamente e rapidamente 90% dos medicamentos que lhe foram apresentados. Para
avaliação de combinações medicamentosas o resultado atingido foi de 70%, atingindo assim a
fiabilidade esperada.
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Chapter 1
Introduction2
Nowadays, the general profile of the population in most countries is a lot different from what it4
was 20 years ago. With the technological and scientific evolution in the last decade the health
care service has improved exponentially. All these factors together have resulted in the ageing of6
population and an increase in number of elderly population.
Based on data collected from [WHO13], the life expectancy specifically in Portugal has in-8
creased from 74 years on 1990 to 79.4 years on 2009, which means an increase of 5.4 years,
a significant increase even for a developed country. It is possible to notice a clear discrepancy10
between the developed countries life expectancy and 3rd world countries in the available data.
Africa’s life expectancy in 2009 is about 54 years old, in contrast to the Europe and America’s12
which is 20+ years higher.
The elderly population will have a higher falling rate due to age-related changes and frailty, so,14
falling can eventually lead to very serious physical and/or psychological outcomes. In the worst
case scenario it can lead to death, but it can also lead to incapacitating injuries, depression, fear,16
suffering, loss of independence and as a result, decreases in life quality. Those kind of scenarios
can become a problem that will expand to the family of the patient, since it will have economical18
and social consequences and will be time consuming[Ga11].
The recent increase in numbers of the elderly people places the problem of falling in the20
community as one important matter to be attended, since the health care keeps improving and
there will still be an increasing portion of the population in elderly stage of life. We will reach a22
point where it will be too difficult to keep track of all the registered cases and accompany them
individually in a non automated way.24
It is now proven by a vast number of studies conducted all over the world[KPY+03, HLL07,
RCV03, EBM02, ZDH+06] that fall prediction by multi-medication is an issue and can be pre-26
vented or at least minimized by changing some patient habits and adopt precautionary measures
in their daily activities[Dye07]. An article on American Academy of Family Physician (AAFP)28
states that:
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The side effects of some medicines can upset your balance and make you fall. Medicines
for depression, sleep problems and high blood pressure often cause falls. Some 2
medicines for diabetes and heart conditions can also make you unsteady on your
feet. [Phy00], p.2173 4
A better watch on the patient during a critical stage of the medication will decrease the risk of
falling and consequently, the effects related to the fall. If we could be capable of identifying that 6
critical stage the advantages would be immense.
Currently, are several studies under development that research on the side effects of multiple 8
medications. However, the majority of those studies are based on a fixed population limiting
the scope of results to the events verified in that scenario. In this regard, this project aimed at 10
developing a tool capable of analysing the medication being used by a patient and assess the
situation by identifying the risks related to falls in a specific given scenario regarding the amount 12
and types of medication. This will ideally help to prevent possible falls and consequently injuries
or traumatic experiences that could lead to a decrease in quality of life for the patient and their 14
families.
This dissertation intends to study the relation between the single, multi-medication and the 16
falls in the older population. A specific tool was developed for this purpose. We have identified
types, families and groups of drugs in order to identify their substances and possible combinations 18
that might lead to a fall risk increase.
1.1 The Problem 20
Falls are a serious concern nowadays, specially in the older population. There are some methods,
studies, initiatives and tools available in this field to prevent, predict and identify falls [FPC05, 22
Agi10, SPA09], but they revealed themselves not viable to this specific purpose of risk identifi-
cation on drug usage, mainly because it is not their specific goal. With the recent increase of the 24
older population this problem became even more serious. Therefore fall prevention is becoming a
challenge of greater importance to the well being of the elder population. 26
It is a proven fact that medication can lead to a higher risk of falling [Phy00, KPY+03, HLL07].
The side effects of each drug are available on the leaflets, this includes all types of associated side 28
effects and may even mention fall risk itself. However, with the combination of 2 or more drugs,
unreported and unexpected side effects may occur. The usage of 2 distinct drugs with individual 30
side effects unrelated to falls can lead to a side effect that will increase the falling ratio. Some
of the combined side effects are already reported and known, but due to the huge number of 32
medicine available to us, it is currently impossible to report all the combined side effects. The
known side effects from the drug interactions are normally checked by the healthcare professional 34
when prescribing multiple drugs, but since it is a manual process there may be some details or
drug interactions that may go unnoticed. 36
The majority of existing studies regarding this matter are performed in a clinical setting and
are only available to a limited part of the population. In this project we intend to use some data 38
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gathered by these studies to identify the main drug families/groups/types that are related to high
fall ratios.2
The technological development and computational power available today will make it possible
for us to set up an automated system capable of analysing a patient’s drug usage and identify the4
fall risk according to the drugs properties and interactions.
1.2 Project6
Polypharmacy effects in the elderly population is a dissertation that was proposed by Fraunhofer
Portugal Research Center for Assistive Information and Communication Solutions (Fraunhofer8
AICOS)1. Currently this institution is developing several projects related to falls, mainly with the
objective of using the sensors available in mobile phones to evaluate the ambulatory information.10
By recording and tracking the way people move it is possible to study the occurrence of falls and
assess if the user is standing, sitting, ruining, among other possible states.12
It is possible to apply this knowledge in a vast number of subjects, and getting the record of
the medication currently used by them will allow to make an analysis on the side effects of the14
polypharmacy in multiple cases.
Our specific part in this, is to develop a tool to evaluate the relation between the medication16
being taken by a patient and the fall risk associated with that same medication. This work could
eventually be integrated with the currently existing projects in Fraunhofer AICOS to create a more18
complete and effective evaluation/prediction tool for falls.
In the development of the project a lot of information about the individual drugs that are20
being used in different cases will be available. We will identify the drug, link the drug to a specific
concept, and from there evaluate that drug according to the available databases. Knowing the type,22
family or even components of the drug makes it possible for us to make a study on the correlated
fall risk that is associated with that same drug. The information gathered will be stored in a pre-24
developed and pre-populated knowledge representation model that we will study and improve with
new structures and information related to our study.26
1.3 Goals and Motivation
Since currently the portion of the elderly population is increasing it is of great importance to pro-28
vide a system that can do something about the vast array of problems related to multi medication
and falls that are presented in this part of the population. The fall itself represents only a part of30
the problem that we intend to solve, or at least minimize. It is usual nowadays to see older people
using multiple medication daily, sometimes for the same disease, and the negative consequences32
of the mixed side effects can, in some cases be very severe. Those cases that may happen without
notice from the healthcare professional and may bring severe consequences to the patient.34
The project has the following main objectives:
1http://www.fraunhofer.pt/en/fraunhofer_aicos/about_us.html
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• improve/update a knowledge representation model that will be capable of representing the
medical drugs and relevant associations 2
• Identify the system entries as substances or trade names
• If the entry is a trade name the system must be able to identify the active substance 4
• Relate the entries to the respective concept or create the concept if not found
• Update the concept if possible with external data regarding the drug class/family/type 6
• Update the side effects if possible/needed
• Evaluate the risk of the entry drugs individually according to the gathered information 8
• Evaluate the drug interaction risks to the given drug set
Doing all the steps of this process using human resources would take a lot of manpower and 10
research time.
The final goal of this project is to make possible the analysis of the usage of multi-medication 12
in the elderly populations automatically. This project will focus exclusively on the components
and side effects related to the falls. 14
1.4 Structure of the document
This document is divided in 7 different chapters. 16
Chapter 2, background and literature review, reports the study of the problem and explains the
reasons for the problems as well as the possible ways to solve them as well as the existing projects 18
related to the thesis subject.
Chapter 3 specifies the platforms and necessary information for this project. Here we conduct 20
a detailed study of the technologies we used and sources for the information we need to proceed
to the drug evaluation. 22
Chapter 4 specifies in detail the modification performed in the existing data model and struc-
ture in order to adapt it to our purpose. We will justify the modification individually and explain 24
the approach.
Chapter 5 explains how the core of the system works. It will explain all the process and data 26
access used during the fall risk evaluation process. The whole process and sub processes are
exposed using diagrams and textual explanation. 28
Chapter 6 contains information on the matching tests and verification of the accuracy of the
various results we’ve reached following the approach presented in chapter 5. 30
Finally, conclusions are presented in Chapter 7 where we mention the problems we have over-
come and possible directions to address the ones that persist. 32
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Chapter 2
Background and Literature Review2
This chapter will present a literature review on polypharmacy, possible solutions and important4
background concepts. This review will be focused in the elder population. The information will
be presented considering the project description and the proposed objectives, so that the proposed6
approach can be introduced upon a careful investigation of the background existing literature re-
lated to falls and polypharmacy in the elderly population.8
2.1 The ageing process
In the last century, the average life expectancy has increased substantially, mainly in the developed10
countries [WHO13] . This happens due to a series of changes in lifestyle, personal habits, sanita-
tion, science and technology in the society. All these factors will contribute to decrease disease-12
related deaths in the population, and consequently people will have a longer life expectancy which
will lead to an increase in the elderly population [FTW+01].14
The figure 2.1 represents the life expectancy per country in Europe. The information available
dates from 2009 and the source is the World Health Organization [WHO13] .16
The study of falls in this thesis will focus on the elderly people. "Elderly people" is a vague
definition, because it depends on the place, culture and economics where we apply it, but in abso-18
lute terms and for this thesis "Elderly people" is considered to be someone 65 years old or more.
Since birth, a human being’s body will be constantly accumulating changes which will grad-20
ually increase susceptibility to disease and death. This natural process that occurs in every living
being is called "Ageing process" and its definition according to [Har81] is the following:22
Ageing is the progressive accumulation of changes with the time that are associated
with or responsible for the ever-increasing susceptibility to disease and death which24
accompanies advancing age. [Har81], p.7125
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Figure 2.1: Life expectancy in Europe 2009
The wear of the organs and body will depend on the care and usage during the patient’s life.
Due to this "Ageing process" the older people will consequently have a lower capability to deal 2
with eventual diseases, virus, falls or other kind of health issues. They will also eventually start to
lose cognitive and physical skills that are as well related to the ageing process. 4
The ageing itself is not the only process that contributes to a decreasing in the cognitive and
physical skills. This is influenced as well by genetics, environment and social factors. With all 6
these variables and in such a vast population we will have a lot of subject profiles with the same
age that may behave differently with the variation of the factors mentioned. 8
The ageing process can be separated in 3 distinct modes. First we have the usual/normal
ageing process which refers to the most common way people age. This first process is defined 10
by a gradual decline in physical skills which will lead to other problems like diseases, loss of
mobility and other problems that will eventually result in complications and death. Then we have 12
the pathological ageing. Pathological ageing is different from usual ageing since it is applied to a
group of subjects that are predisposed to certain diseases or have negative lifestyle habits that may 14
have serious consequences leading to a premature death.
The other ageing model is the successful ageing, which may be mistakenly interpreted as a 16
longer life, but instead is a qualitative reference to the ageing process where the usual ageing
problems do not manifest so intensely and the subject can have a life quality above average for 18
his/her age. This kind of ageing can be achieved by regular physical care, a balanced diet and
avoiding bad habits like tobacco or drugs [Gar10]. 20
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2.2 Falls
Falls can be normally associated with old age. The fall itself may not be the main problem in this2
case, but the long or short term injuries caused as a consequence of the fall and the wear of the
body. This is a problem that will aggravate according to the age and other factors of the victim.4
Patients with diabetes will have trouble healing possible wounds and a huge array of complications
may come from there. Due to the increasing numbers of elderly people within our community the6
study of the falls in older people has been increasingly important in order to prevent long and short
term injuries and improve the quality of life in this part of the population.8
Definition
There are many causes to a fall and many definitions of falls according to the cause or motivation10
of the fall itself. Here we will check some literature and medical concepts on falls.
According to the International Classification of External Causes of Injury (ICECI)[ICE04],12
a international entity related to the World Health Association (WHO) that is responsible for the
classification of all the external causes of injury, a fall is a descent or drop by force of gravity,14
"nonsyncopal event not attributable to sustaining a violent blow, loss of consciousness, stroke or
epileptic seizure" [ICE04].16
A book published by the Agency for Healthcare Research and Quality [SH08] states that a
fall may be precipitated by intrinsic or extrinsic factors. Intrinsic factors are the ones that have18
a physiologic origin, and extrinsic factors are those precipitating from environmental or other
hazards. According to that same book, the definition of fall is20
“an event which results in a person coming to rest unintentionally on the ground or
lower level, not as a result of a major intrinsic event (such as a stroke) or overwhelm-22
ing hazard” [SH08].
The International Classification of Diseases, Ninth Revision, Clinical Modification, (ICD-9-24
CM) 1 produced a series of codes that are used to categorize and separate the various types of falls.
There we can see the following description:26
Accidentally bumping against moving object caused by crowd with subsequent fall
(E917.6); Fall on or from ladders or scaffolding (E881); Fall from or out of building28
or other structure (E882); Other fall from one level to another (E884); Fall on same
level from slipping, tripping, or stumbling (E885); Fall on same level from collision,30
pushing, or shoving by or with another person (E886); and Other and unspecified
fall (E888).48 In the inpatient care setting, E888 is the code that is typically used to32
record a fall in a medical record.
Morse [Mor09] says that falls can be classified in 3 different categories:34
1http://www.cdc.gov/nchs/icd/icd9cm.htm
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• Accidental falls - related to extrinsic factors, such as environmental factors like slipping,
tripping or some other kind of mishap. Other causes for this kind of fall are errors of 2
judgement, such as leaning against a curtain thinking it was a supportive wall. Accidental
falls may also occur if the patient loses balance when ambulating. 4
• Anticipated physiologic falls - caused by intrinsic physiological factors, such as confusion
os other kind of disorientation. The kind of falls that normally occur with the patients 6
identified as fall-prone due to the high falling risk.
• Unanticipated physiologic falls - derived unexpected intrinsic events, such as a new onset 8
syncopal event or a major intrinsic event such as stroke. Basically this kind of falls will
occur in patients that apparently are not likely to suffer from a fall due to physiological 10
factors. It is the kind of fall that cannot be predicted before the first occurrence.
2.2.1 Incidence 12
Here we will illustrate and study that concept based on real studies and data, starting with a tech-
nical report by the public health Agency of Canada [SPP10] . This report is based on the death 14
statistics since 1997 to 2002. The report only uses data from people with 66+ years old and focused
on deaths due to unintentional falls. 16
Figure 2.2 represents the distribution of fall occurrences in a limited sample of the population
and divided by age group [SPP10]. It is clear from an analysis of the graph that the age is a factor 18
on the occurrence of the falls.
Figure 2.2: Deaths due to falls, by age group, age 65+, Canada, 1997-2002 [ORM09]
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Another research [ORM09], by the Healthcare Cost and Utilization Project (HCUP) reached
conclusions regarding the evolution of the falling patterns with age. Figure 2.3 shows in a graph2
the recurrence of falls according to the age of the subjects.
Figure 2.3: Rates of Emergency Department visits for injurious falls among elderly
2.2.2 Impact and Consequences4
According to Tonarelli [Ton10] falls occur every year in 1/3 of the population with >65 years old.
This statistic will take even larger dimensions if we talk about those who already had a fall. Here6
we will study some of the possible outcomes of a fall and the impact that may be forced upon the
victims of falls.8
• Hip Injuries - the result of falling in the elderly result most of the times in bruises, traumas
and fractures, mainly on the hips, spine, arms, ankles or legs. Reports from the American10
Academy of Orthopedic Surgeon say that approximately 1/4 of those who have this injury
die within a year and 50% lose mobility. This means that the victims of this type of injury12
will become dependent on their daily life which may cause other type of problems. Hip
injuries are a rare problem in the younger people, but it is a kind of injury whose probability14
increases with age. For example, the rating on hip injuries on 85 years old subjects are 15
time higher compared to that same problem on a 56 years old patient [Ton10].16
• Impaired Functioning and Mobility - Hip injuries are only one of the possible conse-
quences of a fall. We can name some other grave injuries that can change drastically the18
daily life of a person. It is normal for everyone to gradually lose some function of their
bodies over the years and that can lead in some cases to the lost of independence. Simple20
things to a middle age person like climb stairs, dress, rise from a chair or bed, walk and oth-
ers things can no longer be doable to the elderly due to the age alone. A study published in22
the journal Age and Ageing [MGMO12] revealed that functioning decline was observed in
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more than 35 percent of elderly who had fallen at least once in the previous year. 15% of the
studied population had more serious mobility problems with basic functions like walking, 2
cycling and other kinds of basic mobility functions. The main sub consequence of mobility
lost is that it is a exponential problem. The more mobility an elder looses the more it will 4
loose in the future due to the lack of body usage and degradation of the muscular tissues and
bones. 6
• Fear of Falling - the same study mentioned above reached a conclusion that shows that
falls can have a social consequence on the patient. This means that the victim of the fall can 8
withdraw from social activities like visiting friends or relatives or even go out for a walk.
The mobility problems that can result from the fall may have an important part in this, but 10
the fear will contribute in part to the decrease of basic activities. The lost of confidence in
the ability to move around is the reason for the development of what we mention here as 12
"fear of falling". The study from Vrije University shows why the victims of falling tend
to isolate themselves and all the consequences mentioned above may cause vulnerability, 14
depression and another psychological problems that will inevitably reflect in the quality of
life. According to [SSvD+08] fear of falling will lead to similar consequences as the ones 16
presented to impaired mobility function:
The main consequences were identified as a decline in physical and mental per- 18
formance, an increased risk of falling and progressive loss of health-related qual-
ity of life. 20
2.3 Side Effects
The likelihood of illness is increased with the ageing process. Directly connected to this logic is 22
an increase in medical drugs usage. A study from the year 2000 [MB00] reveals that in the USA
people over 65 years old consume over 40% of the sold medicine, even though they only represent 24
13% of the population. Today the life expectancy is slightly higher, but the tendency is the same.
The same scenario is presented to us in the UK where 65+ years old populations represent 18% 26
of the total population but still consume 45% of the medical supply in the country [MB00]. The
normalization on the usage of such high number of medical drugs will cause for some side effects 28
to go unnoticed. If we add the low health expectations on this kind of patients that may make them
less likely to complain we have a vast set of factors that contribute to the side effects accumulation. 30
This is a problem that may be solved with some work by the health professionals.
An extensive search revealed that a list of side effects related to falls is not available, at least a 32
complete and validated one. In this case scenario the obvious choice was to investigate and create
one. One way for us to check for the fall risk of a specific drug is to evaluate the side effects 34
directly related to that medicine. In order to do this it is crucial for us to do a background check
on fall related side effects. Another way for us to investigate the most common side effects related 36
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to falls is to evaluate the recurrence of side effects in potentially risky drugs. So, for us to get the
maximum number of fall related side effects we will use both methods and present the results.2
Background
According to a study [RJR94] the most usual side effects connected to fall include gait and balance4
disorders, weakness, dizziness, environmental hazards, confusion, visual imparity and postural
hypotension, lower-extremity weakness, gait and balance instability, poor vision, cognitive and6
functional impairment. In this list, some connections to falls may be obvious, but others not so
much. In this study, the most common problems were related to gait and weakness problems that8
result in nearly 1/4 of the fall cases. Lower extremity weakness was another big contributor to the
fall ratio, as 48 to 57% of the patients suffer from this. Some of these problems exist on this kind10
of population only due to the fact of their age. The drug side effects normally act as an aggravating
factor that will increase the severity of those problems.12
According to [MGMS80], healthy older persons will score on average 20 to 40% lower on
strength tests when compared to young people. We still have to take into account that a good14
part of institutionalized older people are not healthy, so the combination of all these factors will
increase exponentially the related risk.16
Awareness or mental disparity effects like poor vision, cognitive impairment, confusion and
dizziness can easily be associated with falls since the subject will lose motor, evaluation and re-18
acting time capabilities. Another type of issues that may lead to falls are those related to physical
problems or disabilities. Side effects like gait balance, weakness, lower-extremity weakness, bal-20
ance instability and cognitive impairments are listed on this class of problems due to the difficulty
in reacting or avoiding a fall situation by the subject.22
2.4 Polypharmacy
The motive that leads to a fall can vary and we can identify a series of risk factors. One of the24
main risk factors in older people is correlated with certain types of medication, and the combina-
tion of multi-medication generally increases the associated risk. This case scenario is even more26
dangerous when the mixed drugs are already by themselves considered of high risk for fall related
problems.28
Here we will discuss the effects of various types of medications on falls so we can evaluate the
associated risk per medication type. Some investigations/studies done before reached conclusive30
results between the medication types and the probability of falling in older people.
Most of the studies we consulted were done targeting a specific part of the population. The32
limitations of each study vary on the gender, age group and targeted drug family/group/type. The
vast majority of the studies are done in a controlled trial and then, achieve conclusions when34
compared to a control group. Some other studies use records from healthcare institutions and limit
them by the trial by specific requirements. A study published in the British Journal of Clinical36
Pharmacology [ZDH+06] revealed that it is possible to assess a fall risk based only in the number
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of drugs that the subject is currently taking. However, this kind of risk measurement is not accurate
and may be misleading, since it does not take into account many other fundamental factors. Figure 2
2.4 represent the results by the British study [ZDH+06]:
Figure 2.4: Polypharmacy fall risk according to the number of drugs[ZDH+06].
We can clearly see a direct relation between the number of drugs taken (X axis) and the Fall 4
Odd Ratio(Y axis) value in comparison to a control group, which proves that there is a relation as
we anticipated. The study also states that with the increase in the number of drugs being taken, 6
the probability of taking risky drugs also increase. This is why the verification of the drug types
and risk must be done for all drugs being used. 8
In the study, the drugs considered risky were mainly Central Nervous System drugs and diuret-
ics. For us to get definitive conclusions we have to evaluate the results of multiple studies/clinical 10
trials.
2.4.1 Definition 12
The term polypharmacy refers to the group of medications one person may be taking. It comes
from two Greek root words: poly, meaning many, and pharmakeia meaning medicines or drugs. 14
It is generally used when that one person is taking multiple medications, or when the drugs have
been prescribed by many doctors, and may not have been coordinated well. This is usually a 16
problem for adults with advanced age that may have more than one medical condition. Since they
need medication to more than one disease there could be some extra symptoms due to the mix of 18
medication, side effects that are not mentioned in either one of the original medicine.
2.4.2 Definitions and classification of medication types 20
At this point it is important to say that medication types, families and groups overlap very often.
A family of drugs can contain substances from various families or a substance may be a part of 22
several drug groups. We will mention the cases we have found during this literature review.
12
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2.4.2.1 Benzodiazepines
Several other studies [PMT+01, PVR+00, NHMP96] revealed benzodiazepines as one of the most2
dangerous drugs when we are talking about falls in the elderly. Benzodiazepines are a chemical
group whose chemical core structure is composed by benzene and diazepine. Benzodiazepines4
may be a subgroup of the Antidepressant ,Hypnotic, Sedative, Anxyolitics, Antiepileptics, and
some other Central Nervous System(CNS) related drugs. During this study we found out that this6
kind of drugs have a top priority when it comes to fall risk prediction.
The figure 2.5 represents a part of the study [PVR+00] where we can clearly see the impact of8
benzodiazepines, among other factors, on the patients. The first column represent the Odd Ratio
when compared to a control group and the second column represents the standard deviation.10
Figure 2.5: Multivariate analysis of risk factors for falls in 7908 hospitalized patients[PVR+00].
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2.4.2.2 Antidepressants
Antidepressants are a psychiatric medication which is normally used to alleviate mood disorders, 2
such as major depression and dysthymia and anxiety disorders such as social anxiety disorder. The
effects of antidepressants will take time to take action on the subject and are usually administered 4
for long periods of time, from months to years.
There are two main types of antidepressants, the selective serotonin reuptake inhibitors (SS- 6
RIs) and the tricyclic antidepressants(TCAs). Generally, in older patients the use of TCAs is
preferable; however, SSRIs are associated with a reduced fall ratio [RBBL03] . 8
On the other hand, another study revealed that the fall ratio was slightly higher with the use
of SSRIs (6.3%) compared to TCAs (4.76%) [HLL07] . Regardless, both studies agreed that the 10
risk of falls remained high in the long-term usage of antidepressants. The worst case scenario is
verified when a patient uses both types of antidepressants which result in an even higher fall ratio. 12
This ratio is directly proportional to the antidepressant dosage.
TCAs and SSRIs were unidentified in various articles or clinical trials and proven to be one of 14
the main drugs classes related to falls in older persons [Hub03, AWA01, LAM+98].
With participants who had no exposure to antidepressants as the reference category, 16
the adjusted odds ratio for hip fracture was 2.4 (95% CI 2.0–2.7) for exposure to
SSRIs, 2.2 (1.8–2.8) for exposure to secondary-amine TCAs, and 1.5 (1.3–1.7) for 18
exposure to tertiary-amine TCAs. For all types of antidepressants, current use was
associated with a higher risk of hip fracture than former use. The odds ratios for 20
hip fracture were higher for new current users than for continuous current users
in all three drug classes. The proportion of current use in the low-dose range was 22
22% for SSRIs, 50% for secondary-amine TCAs, and 58% for tertiary-amine TCAs.
[LAM+98], p. 1303 24
2.4.2.3 Antihypertensive drugs
Antihypertensive drugs are a type of drugs used to treat high blood pressure or hypertension in 26
order to avoid complications like strokes or myocardial infarction. The blood pressure-lowering
effects can result in some side effects like orthostatic hypotension and dizziness that represent a 28
serious problem.
Orthostatic hypertension is a form of hypertension in which a person’s blood pressure suddenly 30
falls when standing up or stretching and can occur briefly and occasionally in anyone, but it is
particularly usual among the older people. 32
With this kind of drug in the right dosage it is possible to improve the cerebral and systemic
vascular response to hypotensive stress. Consequently, there is no association of antihypertenside 34
drugs with an increased risk of falls. So, and according to [RBBL03] , there should be no reason
for a major falling ratio problem associated with Antihypertensive medicine. 36
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2.4.2.4 Anticonvulsants/Antiepileptic drugs
Anticonvulsants, also known as Antiepileptic drugs are prescribed to treat a range of medical 38
conditions like seizure disorders and epilepsy. Among those are diseases like bipolar disorder,
fibromyalgia, and pain caused by nerve injuries or other conditions. There are reports that associate2
this kind of drugs to be directly linked to an significantly higher risk of falling in elderly people,
specially women. The effects of anticonvulsants in the central nervous system was identified as4
the cause for this behaviour [RBBL03]. It is important to say that anticonvulsants may contain a
part of other risky drug classes like Beznodiazepines.6
2.4.2.5 Anxiolytics
Anxiolitics are another CNS drug. Several studies and clinical trials [LPE03, MM97, RCV03]8
revealed Anxiolitics and other CNS drugs to have a direct relation with the fall ratio verified in
older and some middle age subjects. There are some anxyolitic drugs that are benzodiazepines.10
Those are the main cases to worry about and where we should focus our attention. The remaining
anxyolitics also present some increase in fall ratio but with much less significance. Anxiolytic12
drugs are also known as minor tranquillizers.
2.4.2.6 Beta Blockers14
Beta blockers are a class of drugs that, as the name states, block the beta receptor agents. This
kind of agents are part of the sympathetic nervous system and are responsible for actions related16
to stress reaction and adrenaline situations. The normal target for beta blockers are problems
related to cardiac arrhythmias and hypotension. The relations of beta blockers and falls is studied18
in [RCV03] where we can read that:" Recurrent falls were reported 2.0 times as often among
beta-blocker users as among non users, after adjusting for cardiovascular disease".20
2.4.2.7 Muscle Relaxants
As the name indicates, muscle relaxants are all the drugs that affects skeletal muscle function22
in order to decrease the muscle tone. Normally the usage of this type of drugs is to decrease
involuntary movements or spasms. The connection to falls here is pretty straight forward. These24
effects may reduce the capacity of the subject to react in a fall situation by reducing the response
time of the muscles or even cause that same fall situation.26
2.4.2.8 Opioids
Opioids are also refereed in some articles as a possible fall contributor. However, this association is28
controversial, since while there are studies that revealed a distinct and clear relation of these drug
types to falls [EBM02], other studies says that there are no indicators to reach that conclusion30
[KPY+03].
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2.4.2.9 Psychotropics32
An article in the Journal of gerontology [HLL07] reviews multiple clinical trials ad combines all
the available information on medication and falls in order to reach some interesting conclusions.
This study says that: 2
Central nervous system drugs, especially psychotropics, seem to be associated with
an increased risk of falls. The quality of observational studies needs to be improved, 4
for many appear to lack even a clear definition of a fall, target medicines, or prospec-
tive follow-up. Many drugs commonly used by older persons are not systematically 6
studied as risk factors for falls.[HLL07], p.1
Almost all of the drug types listed above are Central Nervous System (CNS) drugs that are 8
known to have some unwanted side effects, mainly related to the individual perception and body
control. After checking individually the medicine types listed above it is important to focus on 10
the fact that the conclusions pointed for each drug type individually may not be the same if we
combine two or more of them. When the scenario is different and the patient is taking several 12
types of pharmacological drugs it is possible to observe different outcomes that are not listed in
any of the medications. 14
In order to avoid undesirable side effects related to falls it is possible to use medication in order
to to cancel, minimize or maximize those side effects. Sadly, this solution is not viable due to the 16
costs and possible complications related to the side effects of polypharmacy. We can mention as
another possible scenario, we may consider, the usage of 2 drugs, neither of them with risk falling 18
side effects, may lead to an increased risk due to the mixing of those drugs, possibly creating side
effects that are not listed. The objective of this thesis is, among others, to identify some of those 20
cases.
2.4.3 Risk factors 22
Since we are studying the impact on falls only in the elderly population we can associate most of
the causes to that same factor, the age itself. Elderly people are most likely to fall because they 24
have one or more of the following risk factors [Ton10]:
• being under the effect of certain medications, such as laxatives, diuretics, antidepressants 26
or sedatives;
• suffering from conditions that affect balance, such as Parkinson’s disease, arthritis, multiple 28
sclerosis and stroke, or that cause sudden drops in blood pressure, like hypotension;
• having medical problems that result in the need to get up from bed at night or rushing, like 30
insomnia and incontinence;
• using a walking aid, like a cane or walker; 32
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• suffering from Alzheimer’s disease or other forms of dementia
The age itself is a risk due to age related changes in the body. Problems like vision issues, 34
balance, muscular problems, gait and psychological factors are all related to the age and will
increase the risk of falling [Ton10]. Even during the fall event, a capable body will have a much2
better response to avoid or minimize an injury. Physical strength and reflexes are very important
in the process and both are factors that may be compromised when we talk about a elder person.4
2.5 Fall risk evaluation system
In order to evaluate a specific drug risk we have to assign a specific class to that drug. This drug6
evaluation has to be done according to a standardized pattern, so we can get information sources
and has to be sufficiently specific to identify the subsets we want. After some investigation we8
found a fitting solution to this classification problem, the Anatomical Therapeutic Classification
System (ATC).10
2.5.1 Anatomical Therapeutic Classification System
The Anatomical Therapeutic Chemical (ATC) Classification System was created in 1976 by te12
WHO Collaborating center for drug Statistics Division [WHO13].
This pharmaceutical drug coding system seeks to divide drugs into specific groups accord-14
ing to specific aspects. Information like the organ/system they act on, therapeutic or chemical
characteristics will be taken into account to evaluate the drug.16
ATC can have more than one code per substance, since one specific substance can be used in
several Anatomical groups:18
Acetylsalicylic acid (aspirin), for example, has A01AD05 as a drug for local oral
treatment, B01AC06 as a platelet inhibitor, and N02BA01 as an analgesic and an-20
tipyretic.
Several different brand names can share the same ATC code, since the active substance is22
the factor that is taken into account when we attribute the ATC code to the Drug. The figure
2.1 illustrate the classification code for Acetylsalicylic acid divided specifically in the 5 ATC24
categories.
This classification system can be very useful since some of the drug types we have to identify26
are mid-levels like Antidepressants (N06A) which is a 3rd level sub class and we can identify all
their subclasses as potentially risky.28
2.6 Related projects
Currently, due to the increase on the number of people using smart phones, there are many studies30
concerning the fall detection that use the capabilities of these devices[KP09, CLC+11, DBY+10].
17
Background and Literature Review
Table 2.1: Nonlinear Model Results
ATC CODE Description#1
A Alimentary tract and metabolism
A01 Stomacological preparations
A01A Stomacological preparations
A01AD Other agents for local oral treatment
A01AD05 Acetylsalicylic Acid
The reason for this is that the mobile phone is always with the subject and there is no need to get32
new equipment if the patient uses a smart phone. Nowadays smart phones have a vast array of
tools capable of identifying possibles clues about the state of the patient. Using accelerometer,
camera, compass or any other devices available, a smart phone can process the data and brings up 2
a conclusion. Today there are mobile phones with more computing power than the average PC,
which makes this process very fast and easy to implement. 4
The detection of falls is a part of several projects at FhP, but the main objective in this disser-
tation is not related to the fall detection. Instead we will analyse and reach conclusions about the 6
medicine currently being used by the patient. We will evaluate the list of drugs currently used by
the patient, place the drug in a certain class and from there assess the fall risk associated with the 8
drug.
There are several studies regarding multi medication and our research revealed that some of 10
these projects have similar objectives and methodologies. However, we did not find any particular
initiative that is developing a system with the exact same objective, a polypharmacy study related 12
with falls in the elderly population.
Instead we found several projects that use the mobile phone to evaluate ambulatory or health 14
status on the patient based on the phone sensors (applications like "Smart fall Detection" or "Fall
detection v1.0"). A specific study and concrete application was developed in Bolgana, Italy 16
[TMC11]. We also found several applications evaluating or informing about drugs, but none of
those applications have the specific objective to relate the medicine with falls. 18
2.7 Overview
With the literature review concluded, we can identified a clear problem to the elderly. The existing 20
information regarding drug classes, side effects and drug-drug interactions allow us to create a
automated system that can analyse the information and assess the fall risk to a specific situation. 22
However, according to our research, such a system was not created by anyone with this specific
objective of evaluating the risk inherent to the multi drug usage and falls. This system would 24
diminish the possibility of human mistake when prescribing drugs to a patient, since it could be
used as a tool that would check for possibly risky situations, and would save time to the healthcare 26
professional.
18
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Resources and Tools
In this chapter we intend to present all the resources that were used along the development of this2
dissertation. First we will present the tool and technologies we worked on and then the resources
and sources of information that were imperative in order to get the information we needed. All the4
tools and technologies will have brief description about their usage and relation to our work.
During the development of this fall risk evaluation system one of the most important challenges6
in this section is the decision of the tools, technologies and resources that should be used for the
given purpose and scenario. During a brief period before starting the project we took some time8
in order to study the possible tools and technologies. All the data gathered at that time will be
presented below.10
3.1 Resources
3.1.1 Pharminx Ontology12
Since our work is to evaluate the available drugs in the Portuguese market we needed a representa-
tion model of medical drugs and a source of information of the available medication. "Information14
Extraction From Medication Leaflets", a dissertation previously developed at FhP [Agu12] pro-
vided all that information and data structure. That dissertation aimed at automatically extracting16
information from medical leaflets and store all the retrieved data using a representation model.
That model is capable of recording the data of the drugs and the relations between concepts. That18
representation model was named Pharminx and was used as the base our project. We updated and
improved the existing model to use it in the evaluation process here. That model was already pop-20
ulated with the information extracted from the Portuguese medical therapeutic records [MH11].
The process of extracting that information was done using automated natural language interpreta-22
tion, which may compromise the accuracy of the records. However, the results achieved during the
test phase of the extraction process points to a high accuracy in the process of identification and24
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evaluation of the interactions with a success rate of approximately 97%. Those records contain
many kinds of information about the pharmacological drugs currently being used in Portugal.26
During the current project the Pharminx model was studied and updated in order to adapt it
to the fall risk evaluation process. All records in the original population were also updated with 2
all the data we had available in our sources. The figure 3.1 is a representation of the original
data model. As we can see there are elements representing the possible data available in the 4
Infarmed records[MH11]from where the information was extracted regarding drug and usage data.
These records are available through the National Authority of Medicines and Health Products and 6
the Portuguese Health Ministry. They contain many different kinds of information about all the
pharmacological drugs currently being used in Portugal. 8
Figure 3.1: Original Pharminx Ontology Model
3.1.2 Unified Medical Language System
The Unified Medical Language System (UMLS) is a compilation of many medical related vocab- 10
ularies with controlled sources. The UMLS can provide a mapped structure of those vocabularies
allowing the user to check the relationship between the concepts and the translation of those con- 12
cepts into dozens of languages. UMLS was developed by the United Sates National Library of
Medicine (USNLM) in 1985 with the objective of encouraging the usage of all the diverse biomet- 14
rical data available to electronic systems. The implementation of this system was a big step to the
generalization of concepts, since it resolve, or at least minimizes the naming problem that exists 16
due to the translation of concepts and medical drugs.
Currently UMLS stores over 1 million biomedical concepts and 5 million concept names 18
spread over 100 incorporated controlled vocabularies and classification systems. This can be
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accessed online using UMLS Terminology Services (UTS) or offline after installing the UMLS 20
database [UA11]
Currently there are three major sources to UMLS database parts:
• Metathesaurus - The Metathesaurus forms the base of the UMLS and comprises over 12
milion biomedical concepts and 5 million concept names.
• Semantic Network - Used to represent the relationship between the concepts, among the4
semantic types that are available in Metathesauros.
• SPECIALIST Lexicon, - a database containing syntactic, morphological, and ortho-6
graphic information for biomedical and common words in the English language.
For our work it is important that we can use and translate medical drugs available in Portugal.8
To do so it is crucial to check the availability of the Portuguese language in the UMLS Database.
We used the latest version available, the 2012AA. According to the documentation this version10
uses 4 Portuguese sources listed below:
• ICPCPOR (ICPC Portuguese) - 1999AA12
• MDRPOR (MedDRA Portuguese) - 2012AA
• MSHPOR (MeSH Portuguese) - 2012AA14
• WHOPOR (WHOART Portuguese) - 1999AA
Using this UMLS version we were able to identify a total of 10,810,680 concepts each one16
of them with an individual Concept Unique Identifier (CUI) and 159,911 Portuguese translations
available.18
3.1.3 Anatomical Therapeutic Chemical Classification System
The Anatomical Therapeutic Chemical Classification System (ATC) was developed and estab-20
lished by the World Health Organization (WHO). In this classification system, all drugs are
grouped in five distinct levels (anatomical main group, therapeutic subgroup, pharmacological sub-22
group, chemical subgroup and chemical substance). Possible modifications on the ATC database
are only made by WHO specialists in their update releases and are based only in scientific articles24
and international pharmacologists 1.
"The drugs are divided into fourteen main groups (1st level), with pharmacologi-26
cal/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharma-
cological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd,28
3rd and 4th levels are often used to identify pharmacological subgroups when that is
considered more appropriate than therapeutic or chemical subgroups [WHO13].2”30
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Figure 3.2: Representation of ATC subgroups [WHO13]
As we can see in the figure 3.2 we have an example of the ATC code for metformin. The five
groups are rated separately and together they form a code describing the medical drug.32
WHO has an available online query system to identify and classify the medical drugs available
in their database. For this system we cannot rely on a system like that since there is no API nor the 2
system is developed to this purpose, so we had to get our own ATC classification database. Since
the ATC database was not free we had to search for alternatives. This search lead us to two ATC 4
sources:
• Alphabetical Listing of ATC drugs and codes - a PDF file with 63 pages and a total of 6
3794 entries from WHO dated from 1999 and published by MSupply, a pharmaceutical
company[Dro00]. 8
• German Institute of Medical Documentation and Information - a PDF/XLS file with a total
of 7602 entries from the Institute dated from January 2012 [WId12]. 10
Both sources are of a considerable size, reliable and complete.
3.1.4 Side Effects Resource 12
The SIDER Side Effects Resource represents an effort to aggregate dispersed public information
on side effects. In 2008, when the database was created no such resource exist in machine-readable 14
form. The creation of this resource was motivated by many requests for data that Monica Campil-
los used during the creation of a paper on the utilization of side effects for drug target prediction 16
[CKG+08]
It contains information on the side effects of several drugs and was extracted from public 18
documents and leaflets. The available information includes side effect frequency, drug and side
effect classifications as well as links to further information, for example drug–target relations. 20
The SIDER Side Effect Resource Database will only be used to complement the information
we already have available on side effects. It is an "extra" that can improve the analysis of fall risk 22
1http://www.whocc.no/atc_ddd_index/
2http://www.whocc.no/atc/structure_and_principles
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related to a specific drug and allow us to get more results during the drug evaluation phase. We
used the latest version available dated March 2012. 24
Figure 3.3: SIDER database statistics
As we can see in the figure 3.3 this database has a total of 4,192 side effects available linked
to a total of 996 medical substances and respective trade names, each one of them connected to2
the UMLS via a Concept Unique Identifier (CUI). This will allow us for an easy connection to
the remaining data structures in the project since we already have the CUI on all the identified4
concepts via UMLS.
3.1.5 Drug-drug interaction information source6
To evaluate the interaction between drugs we must find some reliable source of information that
is able to specify the reaction between two or more distinct drugs. During our research we found8
some options that could be used as source. Most of the sources we found were either a private
source or a product for sale. Those circumstances form an obstacle to the development of our10
drug interactions system. In some cases we contacted the company/individual responsible for the
product to see if it was possible to get partial access to the databases. However we did not manage12
to gain access to the resources. Options will be discussed individually for each of the sources we
found and the reason why we use them or not.14
Sfinx drug Database
Swedish, Finnish, INteraction X-referencing (SFINX) is a drug-drug interaction database that16
belongs to Medbase 3 LTD in Turku, Finland, the Karolinska Institute Department of Clinical
Pharmacology in Stockholm, Sweden, and the Division of Drug Management and Informatics at18
3http://www.medbase.fi
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Stockholm County Council. This database contains concise and validated information concerning
consequences and recommendations on the combination of drugs for more than 12,000 interaction20
pairs.
This database also contains the substance names, Chemical Abstract Service (CAS) number, 2
ATC code and some other informations. SFINX is distributed as an SQL database which is updated
four times a year and delivered as XML-format export file. 4
This solution seems optimal to our system, but after exchanging e-mails with the responsible
at Medbase we were informed that there are no Distributors available in Portugal and even if there 6
was we had no guarantee that the database would be available freely.
Lexi-Comp Drug Interaction database 8
Lexi-Comp Inc.4 is a company that develops clinical information solutions. It also provides
other tools to software development, improve patient safety and elevate the quality of care patients 10
receive. Lexi-Comp provides for customers a Data list of drug-drug, drug-allergy and drug-disease
interactions updated regularly. This data is integrated into an Electronic Medical Record (EMR) 12
and can be accessed through a Web API Solution, a Web Service or XML Datasets. However it
has the same problems as SFINX since it is property of a private entity and can not be accessed 14
freely. In this case we also tried to contact with Lexi-Comp but without results.
Drug Interactions Checker 16
Drug Interactions Checker 5 (DIC) is an online service provided by Cerner Mulum, INC. It is a
service with the objective of easily and rapidly provide interactions information about a vast array 18
of medical drugs to healthcare professionals and usual customers/patients. The problem with this
source is that there is no available API or access form to the data in the format we want it. Besides, 20
the information is only available online and cannot be stored locally, which is a problem for the
type of system we want to develop. This service was created with the objective of simplifying the 22
process of checking for drug interactions for the public with a fairly simple and free access.
Drug DDI Corpus 24
The DrugDDI Corpus is part of a project developed by Isabel Segura-Bedmar and Paloma martínez
with the association of the University Carlos III of Madrid [SBMdPS10]. "The DrugDDI corpus 26
is part of a larger study about automatic Drug-Drug Interaction Extraction. The corpus provides
data for the development and automatic evaluation of systems that annotate and extract drug-drug 28
interactions" 6.
This project uses textual information input regarding the drug combinations obtained from the 30
DrugBank database 7. This database is a rich resource that combines chemical and pharmaceutical
4http://www.lexi.com/
5http://www.drugs.com/drug_interactions.html
6http://labda.inf.uc3m.es/DrugDDI/DrugDDI.html
7http://www.drugbank.ca/
24
Resources and Tools
information regarding approximately 4,900 substances. 32
The corpus is based on a set of 579 texts describing DDI’s(Drug-Drug Interactions) from
DrugBank database. The texts were manually annotated with the interactions with the assistance
of an expert pharmacist, which ensures for the credibility and veracity of this source. A total of2
5,806 sentences were evaluated, containing a total of 3,160 Drug-Drug Interactions.
The result is available to public as XML documents organized by drug names/chemical sub-4
stances regarding the interpretation of each individual DrugBank document in the corpus.
Here we have an example of a sentence correspondence between the text and XML data from6
the corpus:
In vitro studies also indicate that celecoxib, although not a substrate, is an inhibitor8
of cytochrome P450 2D6
Resulted in the XML portion shown in figure 5.410
Figure 3.4: XML representation example from Drug DDI corpus
According to the available information this data source is reliable and is the bigger annotated
corpus for DDI that currently exists. One of the disadvantages we have with this set is that the12
other possible sources mentioned about above have more entries and drug interactions and most
of them include a SQL database that is not available in this option. However, since this source is14
completely free and available we will use it in our project. The first step in the usage of DrugDDI
will be the interpretation and parsing of the xml files to a easier access format. In this case a16
SQLite database.
3.2 Tools and Technologies18
3.2.1 Web Ontology Language
The Web Ontology Language (OWL)8 is designed to be used in applications that need to process20
and have some sense of understanding the information content available. In this description lan-
guage we have specific relationships and dependencies between the data parts of the model. OWL22
facilitates the machine interoperability and uses XML, RDF and RDF-S vocabulary. This kind of
Language is written as XML document and uses the same N-triples and Turtle formats as RDF.24
We can divide OWL into 3 sub languages listed below:
8http://www.w3.org/TR/owl-features/
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• OWL Lite - supports those users primarily needing a classification hierarchy and simple26
constraints.
• OWL DL - supports those users who want the maximum expressiveness while retaining
computational completeness and decidability. OWL DL includes all OWL language con- 2
structs, but they can be used only under certain restrictions.
• OWL Full - it is the most advanced and complete OWL and is meant for users who want 4
maximum expressiveness and the syntactic freedom of RDF with no computational guaran-
tees. 6
3.2.2 Protégé
Protégé9 was developed by Stanford Center for Biomedical Informatics Research at the Stanford 8
University School of Medicine. It is a free, open-source platform that provides a tool to construct
domain models and knowledge-based applications with ontologies. Here we will use it to edit the 10
ontology structure. This means adding or removing properties between elements of the ontology.
It implements a rich set of knowledge-modelling structures and actions that support the creation, 12
visualization, manipulation or edition of ontologies of various representation formats.
To develop this thesis we used one of the last available and stable versions of Protégé, the 4,1 14
since this was the version used in the development of the original Ontology.
3.2.3 Jena 16
Apache Jena10 is a Java framework developed for building Semantic Web applications and in this
case we will use it to edit the OWL population. It provides a vast collection of tools and Java 18
libraries to help the developer to work with semantic web and linked-data applications like the
one we will develop here. In this specific case Jena will be used to manipulate and access the 20
information available in OWL.
Jena is developed so it can cope with this description language in an organized and effortless 22
way for the developer.
Jena is also capable of executing a rule based inference over the RDF or OWL sources. It 24
allows the user to store a large number of triplets/data and be efficient at the same time. One of
the main advantages of using Jena is that it is compatible with SPARQL, which allow us to do fast 26
queries on the model without having to do a manual search that would take much more processing
time. 28
9http://protege.stanford.edu/
10http://jena.apache.org/
26
Resources and Tools
3.2.4 MySQL
MySQL11 is largely known as the world’s most used open source relational database management 30
system. Here we will use it to store all the UMLS information, specifically, the concepts with the
respective Concept Unique Identifiers, translations and relationships. This is one of the distribu-2
tions forms of UMLS, and our choice since it is effective, free, and allows for fast and extensive
queries.4
3.2.5 SQLite
SQLite 12 has a fairly similar structure when compared to MySQL. It uses the same query syntax6
and table/schema organization. However, there are a few specific aspects that make SQLite the
perfect database for small and local databases. First of all SQLite databases will be stores in a8
single file and only one user at the time can have access. The performance of these databases is
similar to MySQL’s when we are using small databases as the ones we will use in this project.10
We will use SQLITE to store the information extracted from PDF, TSC and XLS files contain-
ing ATC, drug-drug Interactions, UMLS subsets divided by languages and side-effects data.12
11http://www.mysql.com/
12http://www.sqlite.org/
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Chapter 4
Knowledge Representation Model14
As mentioned in the introduction of this thesis, this project was developed under the auspices2
of Fraunhofer Portugal AICOS. The project objective is the study of the relation between elder
persons, multi-medication and falls using the technologies available to the society today, to help4
in the study and prevention of the falls in the elderly population.
Our part in the development of this system is the design and development of a tool that is6
capable of analysing the medication currently being taken by a specific patient and evaluate the
possible fall risks associated with that medication. This evaluation can be made by analysing either8
the drug type/family, side effects or a specific drug combination.
In this chapter we intend to present a more technological overview of the knowledge repre-10
sentation model we are going to use and upgrade in the development of this project. Note that
the implementation of the project was done using as base a previous ontology developed here at12
FhP by Bruno Aguiar [Agu12] during his dissertation. We studied the base ontology used on that
project in order to use it and update it with fall related data.14
4.1 Original Model
The knowledge representation model will be used to store the knowledge we have on the variables16
of our system. The original data model has a lot of data that we do not need, but there is no
need for us to delete the relations or the data. We can simply add the parameters we need and18
edit the population updating the records with new information we will use to assess the fall risk.
This will allow for a more complete and extended representation model that can be used with20
other objectives related to the extra information available. The original model, represented by the
Figure 4.1, contains Posology, UMLS records, Time variables, Administration routes, Drugs and22
Drug groups, Dosages, characteristics and Values. The only pre-existing fields that we will have
to use here are the Drugs and UMLS CUI records. The CUI is an important information because24
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it will allow us to connect the concept in the ontology with all the information it has available in
the UMLS records.26
The knowledge representation model will not represent the information in a usual way as it is
represented, for example, in a simple database. It will represent the relations and purposes of each 2
attribute and their dependencies.
Figure 4.1: Schematic knowledge representation model of the original ontology
Knowledge modelling is a process where the information becomes interpretable by a computer 4
using a model of knowledge or standard specification about a certain kind of process limited to a
predetermined field, in this scenario, the drugs and related information. This knowledge represen- 6
tation language or data structure is the only way for the information to be computer interpretable.
We can quote Sowa who says: 8
"Knowledge representation is the application of logic and ontology to the task of
constructing computable models for some domain” [Sow00] 10
In the original model, represented in Protégé illustrated by the Figure 4.2, we can see that we
already have several classes that may be used in our process. 12
• DrugDescription - This class will be one of the main pillars in the development of our
project. We will use the existing structure, mainly in the subclass Drug and add some new 14
structures that will be connected to this class.
• UmlsEntity - Here we can connect the concepts with the entity available in the UMLS 16
database. The subclass we will be using in this case will be Disorder. It will be connected
30
Knowledge Representation Model
Figure 4.2: Knowledge representation model of the original ontology using Protégé
to the Drug as a description to the side effect. All disorders that will be listed as side effects 18
already have CUI’s that will be useful in the evaluation process.
These classes will be very useful in the fall risk evaluation, however, to make a more precise
assessment of the risk we will add several new data structures in the model.2
4.2 Updated Model
The Figure 4.3 represents the specific fields of the ontology that we worked on. All the necessary4
changes and updates to the structure of the data model are presented on Figure 4.3 and are then
explained. Note that the disorder class was used when we updated or added side effects.6
The update we applied to the model was very specific to some parts that we verified before to
be related with the fall possibility. First of all, and as support field to our work and any other work8
that needs to gather information we decided to add the CUI field to the DrugDescription class.
This will help us not only to get the translations to the concepts we need, but will also allow for10
us to get several types of information we may need, such as related concepts, brand names or even
components of a drug.12
One of the big changes on this specific part of the ontology is the addition of various Data Prop-
erties regarding the ATC code. Therapeutic SubGroup, Anatomical main Group, Pharmacological14
Sub Group, Chemical Sub Group and Chemical Substance were the 5 fields added regarding ATC.
These new structures and information will be useful in the identification and interpretation of the16
drug group or family, and this information can be directly associated with a relative fall risk. The
reason why we decided to add these parts of the ATC separately is because it may be useful for us18
in some cases to get only the sub families of a drug.
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Figure 4.3: Ontology modifications/updates
One other part were we did not change the structure, but updated the data was the Disorder20
class. We used this class when adding side effects based on the SIDER database. It is connected
to the Drug class by the "hasAdverseEffect" object property. We also added for each new Disorder
entry the respective CUI. This enables us the translation from English available on the original 2
source to Portuguese, the ontology language. It also allows us to check if the Disorder already
exists in the original ontology. If the disorder already exists we only add a new possible name to 4
it.
A final but even more important addition to the ontology is the "hasInteraction" object prop- 6
erty. This property will be used as a representation in the drug-drug interactions. It is a property
that is responsible for handling the interactions of a specific drug. If the interacting drug is already 8
present in the ontology this class will be directly connected to it. Otherwise and since we do not
want to add new drugs to the ontology population we will just add the CUI regarding the interact- 10
ing drug. That will allow us to have a complete record of the interactions without adding new drug
entries. 12
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Fall Risk Evaluation Process 14
The evaluation of a drug combination case has several variables that will influence the likelihood2
of a fall occurrence. We decided to divide the fall risk evaluation process in two specific parts. First
the individual evaluation of a drug, regarding the identification of the drug properties, specifically4
family/group, related side effects and respective risk. After this process we will check for possible
interactions between the prescribed medication to the patient.6
5.1 Single Drug Evaluation Process
This part represents a very important step in the process of risk assessment. Here we will analyse8
the entry drug names and identify them with a specific data/concept entry. If the respective data
entry for the specific drug is not available in our model we will access the entry by consulting our10
available sources, ATC, side-effects and UMLS, in order to construct a temporary model that will
allow us to make a evaluation even if the ontology population data is insufficient. The ontology12
will only be updated with this new data if the entry already exists but new information is available.
We choose not to add new concepts once the original source of the data model population only14
contains the Infarmed records of drugs available in Portugal and we do not know if we are adding
a drug that respect that condition.16
Figure 5.1 represents a scheme of the simplified Single Drug Evaluation Process (SDEP) out-
side the ontology model. This process will use most of the information sources available to us in18
the project.
The entry name can be given as a Chemical substance or a specific trade name of a pharmaceu-20
tical drug. The SDEP must be capable of conducting an evaluation process in both cases. Since
the ATC, side-effects and UMLSSubset databases only use chemical substance as entries we must22
identify if the entry represents a trade name and retrieve the specific related active substance. To
check the type of entry we received we will use the UMLS database. We opted for the direct usage24
of the UMLS dataset since the amount of information that would be necessary for us to make an
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intermediate database would be too large to make a SQLite database to work effectively, and we26
could lose some entries in the process.
After checking for trade name exception we can finally associate the entry with a specific
chemical substance Concept Unique Identifier (CUI). This code will allow us to translate the chem- 2
ical substance to all the languages available in the UMLS database. The translation is important
since the various information sources we have are from different countries, which means they have 4
different languages.
The next step consists in the retrieval of the ATC code for the chemical substance. Having 6
the language translations for a substance will allow us to use the ATC database search available in
English and German. 8
An identical process as the one verified in the ATC code retrieval will be used to get the
possible side effects on the substance usage. This step is optional, since most of the drugs in 10
the original ontology populated using Portuguese Infarmed records already have some listed side
effects. We use SIDER database to allow us for a more complete side effects listing. 12
The final step in the SDEP is the evaluation of all the data previously gathered in this process
to get a conclusion regarding the fall risk related to the entry drug. This process will be explained 14
step by step ahead in this section.
5.1.1 Entry Evaluation Process 16
The system must be able to face any possible entry and give an adequate response. Ideally, the
entry in this case must be either a chemical substance or a specific trade name. To make this kind 18
of analysis we must rely on the UMLS database. It is possible to verify this type of data since a
large part of the concepts listed in UMLS have the "type" information. Unfortunately, the concept 20
and the type are listed in two different tables. In a database like UMLS where the main table
regarding the concepts contains roughly 10,800,000 entries joining tables would be a problem to 22
the query performance. To do this in an effective way we have done a composed query. This
means that we will do multiple queries instead of one query that would have required a join in the 24
tables. Doing multiple queries may seem like a process that would consume a lot more time, but
since none of these new queries will require a join the execution time will be much faster when 26
compared to a single query that would do all the work.
The tables 5.1 and 5.2 represent the relevant fields in the tables MRREL and MRCONSO from 28
the UMLS database.
Column Description
CUI1 First Concept Unique Identifier for chemical substance
CUI2 Secondary Concept Unique identifier for Trade Name
RELA Relation type between the concepts. In this case "has_tradename"
Table 5.1: MRREL relevant content
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Figure 5.1: Project Layout
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Column Description
CUI Concept Unique Identifier
STR String or concept name
LAT The Language of the concept (POR, GER, ENG, SPA, etc...
Table 5.2: MRCONSO relevant content
With this information available we can execute simple queries to know the type of the entry. 30
The queries shown in Listing 5.1 will access the data available in the tables without the need to
execute a join. In this example we use the trade name "Prosom", used for the chemical substance
"Estalozam". 2
1 4
2 Select CUI
3 From MRCONSO 6
4 Where STR = "Prosom";
5 +----------+ 8
6 | CUI |
7 +----------+ 10
8 | C0722865 |
9 +----------+ 12
10
11 Select CUI2, CUI1 RELA 14
12 From MRREL
13 Where CUI2 = "C0722865" AND RELA = "has_tradename"; 16
14 +----------+----------+---------------+
15 | CUI1 | CUI2 | RELA | 18
16 +----------+----------+---------------+
17 | C0722865 | C0014892 | has_tradename | 20
18 | C0722865 | C0014892 | has_tradename |
19 +----------+----------+---------------+ 22
20
21 Select STR 24
22 From MRCONSO
23 Where CUI="C0014892"; 26
24 +---------------------------------+
25 | STR | 28
26 +---------------------------------+
27 | estazolam | 30
28 | Estazolam |
29 | ... | 32
30 +---------------------------------+
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Listing 5.1: Concept query
After understanding the operation to get the trade name relations this query is fairly simple.
First we get the CUI , if it exists, for the entry name. After that, we use that same CUI to know 36
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if there is any chemical substance linked to the given trade name. As we can see in the example
above, the CUI2 represents the chemical substance linked to the entry trade name. 38
This CUI2 represents the connection we want to the entry. At this point we can get all the
information available in the UMLS database regarding this substance/concept. That information2
will be very useful to evaluate the drug entry since it will allow us to translate the drug name into
various languages, a process that can be used to connect the entry with ATC, side-effects or drug4
combinations that may be available in other languages.
5.1.2 The UMLS SQLite Subsets6
As we said before, the UMLS database is the existing database regarding medical concepts and
relations. It compiles all the information available in various reliable sources into one single and8
organized database. This means that we will have on the UMLS database a lot of content that
we will not be using and that content may cause a decline in the query performance. Facing this10
problem we decided to create subsets of the existing database separated by languages. Another
reason for the creation of this subsets is the disk space usage for the UMLS database. It is possible12
for this system to be implemented as a web service. The disk usage would be a problem then,
mainly if we talk about regular backup management and creation. All these factors lead to the14
decision of creating subsets of the UMLS database that can be used in some cases to get faster
results and smaller disk usage. We should mention the fact that we can use the system in both16
ways, either by using directly and only the UMLS MySQL database or by using only the SQLite
language subsets.18
It would be also possible to create a UMLS database using only some types of concepts or
languages. During the development process we also tried this approach that is an option provided20
by the UMLS installation package. However, after limiting the content types and languages we
still identified some concepts missing when compared to the entire set. This may be due to some22
error in our configuration or some problem in the database construction process. Since we want to
have the maximum matching possible we decided to use the complete UMLS dataset and enhance24
the query performance to the best possible point.
Analysis on the matching for both scenarios, UMLS full database and UMLS subsets, will be26
presented in the Result evaluation section. The Table 5.3 represents the structure we used in the
SQLite language subsets and an example for each field regarding the substance Mesna.28
Column Example
CUI C0000294
NAME Mesna
LAT POR
Table 5.3: UMLS SQLite subset structure and example
A total of 4 subsets were created with fragments of the MRCONSO table that will allow us for
a faster query on concept names and CUI, according to the language. The original UMLS MySQL30
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database version we worked on here uses approximately 25GB of disk space. The 4 subsets we
have created (Portuguese, Spanish, German and English) all together will use 427 MB. These32
subsets will be used in the translation of concepts needed in order to connect the other available
sources of information. The UMLS query for translations will only be used if it is impossible to 2
find the concept in the subsets.
Database Size (MB)
UMLSPTSubset 1
UMLSENGSubset 362
UMLSPASubset 64
UMLSGERSubset 1.2
Table 5.4: UMLS SQLite Subsets space usage
As we can see in the Table 5.4 there is a lot more information available in the UMLS database 4
in English, mainly when compared to the Portuguese language. This is due to the largely higher
number of English medical sources. 6
5.1.3 The Anatomical Therapeutic Classificatisuperioron System Matching
The ATC code is one of the main evaluators we use in the risk assessment of a drug. This code 8
will be the bridge between a simple concept name or identifier to a code that we can interpret to
know the kind, family or type of drug we are dealing with. 10
As we mentioned before in the Resources and Tools section, we used two different sources for
the ATC code entries. 12
• Alphabetical Listing of ATC drugs and codes - a PDF file with 63 pages and a total of 3794
entries from WHO dated from 1999 and published by MSupply, a pharmaceutical company. 14
• German Institute of Medical Documentation and Information - a PDF/XLS file with a total
of 7602 entries from the Institute dated from January 2012. 16
The source form of the documents does not allow us for an easy machine readable solution,
so, in both cases, we had to parse the information into a standard form. Since we already had an 18
SQLite interface ready to use we decided to convert both files into two SQLite Databases with the
structure shown in Table 5.5. 20
Name ANATOMICAL THERAPEUTIC PHARMACOLOGICAL
CHEMICAL
GROUP
CHEMICAL
SUBSTANCE
Abciximab B 01 A C 13
Table 5.5: ATC SQLite database schema
As we can see, the structure for the ATC data will divide the code into 5 parts regarding
anatomical, therapeutic, pharmacological, chemical group and chemical substances. Besides the 5 22
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ATC parts we will have the name in the source language that will serve as connector to the entry.
The matching process will try a direct match between the translated name and the database entry. 24
If this does not work it will try another approach for matching that we will explain later on this
section.2
At this point and assuming we found a match we already have the CUI for the chemical sub-
stance and consequently we have several translations that allow us to make the connection with4
the requested ATC.
5.1.4 Side Effects Database6
As we mentioned before the side effects have a unique and important influence in the probability
of a fall occurrence. The original ontology population already had a fairly complete list of possible8
side effects related to certain drugs extracted from the Infarmed records. These side effects are
listed as Disorders, a subclass of UmlsEntitys. However, some drugs had no listed side effects10
and in order to manage a more complete evaluation of the fall risk we decided to get a source
that could complete the data for the substance’s side effects. That is where we used the SIDER12
Database mentioned in Chapter 2.
Once again, this is an option, since we can evaluate the drug using only the available side14
effects that are already in the ontology population. This database is a way for us to manage an
evaluation on the side effects if the drug is not found in the ontology population or if the entry in16
the ontology does not list any side effects. It can also be used to update the existing side effects on
the ontology population.18
The SIDER database was available as 3 tab separated values (tsv) files that we once again
parsed into a SQLite database. This database contains generic and brand names of the medical20
drugs, URL, for the sources used, UMLS CUI’s for the side effects and side effect names, all in
English. It also contains a final .tsv file that has information on the frequency of the side effects.22
However, that information is very incomplete for some drugs, so we did not use this part of the
database.24
The structure adopted for the SideEffects database is listed in Table 5.6. There we can also see
an exaple of one entry for the substance levobunolol.26
Column Example
DrugName Database schem levobunolol
SideEffects cerebrovascular accident+rash+...
CUIs_SideEffects C0038454+C0015230+C0033377+...
Table 5.6: SideEffects SQLite fields and example
Another aspect we must reinforce is that this side effect database only contains side effects
of specific substances or trade names. In the ontology, we often find drug entries with substance28
mixing. This means that we cannot just apply the information in this database to those cases. The
mixing of two substances will not necessarily result in the mixing of the side effects from both30
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substances. So, in case of a multi substance entry, the side effects query will not be made and we
will not add data to the ontology model since we have no way to assure the side effect’s outcome32
in that scenario.
5.1.5 Matching process and Levenshtein distance 2
During all this process several string matching operations had to be done regarding drug trade
names and mainly substances. The process used to do this match will influence the accuracy, 4
matching ratio and efficiency of the process. We can say that per substance we can have normally
6/7 matching processes in the drug evaluation and information gathering process. Here we explain 6
the exact process of matching for these names. The most common parts are listed in Table 5.7 .
Source Matching Purpose
System Entry Ontology to find ontology entity
System Entry UMLS/UMLS subsets to get CUI
System Entry ATC Databases get ATC in case CUI not found
Ontology UMLS/UMLS subsets to get translations/CUI
UMLS/UMLS subsets ATC get ATC
UMLS/UMLS subsets SIDER get SideEffects
UMLS/UMLS subsets DrugDDI Get drug interactions
Table 5.7: Matching process phases
We tried to use the same process every time we needed to link string entities. The process 8
is designed to get the maximum matching possible and be as time efficient as possible. To get a
precise match we first try to apply a translation on the entity. This step is impossible when we are 10
dealing with a name that has not yet been linked to the element itself or its CUI, so we can not
translate. In the other phases we get the array of translations available and try a direct matching. 12
Figure 5.2 represents the work flow on the first step of the matching process.
Figure 5.2: CUI search with direct matching
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At first we use the UMLSPT subset since it is the smaller, faster, and the most likely to cor- 14
rectly translate in the scenario we have. If we do not find a match in the UMLSPT subset then we
try the Spanish, English and German subsets and only as last resort we use the full UMLS dataset.
If we still have no match we will try to get a match using the Levenshtein distance. This resort2
is a bit more time consuming when compared to the attempts we have described before since it
requires more computational power.4
The Levenshtein distance is a string metric measuring system to check the existing difference
between two character sequences. It measures the minimum number of single character edits6
required to change one word into another. So basically, if the two words are the same the Leven-
shtein distance will be 0. Figure 5.3 represents the mathematical formula to calculate the distance8
for two words.
However, this method, as a word difference measurement, may have an issues. The result of10
the method will be only one number that does not take into consideration the original size of the
source words. To solve this problem we used a fairly simple approach: a normalized edit distance12
(NED) [Hee04, KD04]. The calculation of NED 5.1 takes into account the size of both words and
will return a percentage value. This is a simple method where the computational power required is14
little compared to the alternatives. It also is one of the best choices we have on this scenario since
the translations or variation of the names will typically differ in 1 or 2 characters, which comprises16
an already close match.
Figure 5.3: Levenshtein Distance
Mathematically, the Levenshtein Distance between two strings a,b is given by lev a,b(|a|,|b|).18
To simplify we show the following example using the words kitten and sitting.
1 ----- kitten -> sitten (substitution of "s" for "k")20
2 ----- sitten -> sittin (substitution of "i" for "e")
3 ----- sittin -> sitting (insertion of "g")22
NED =
BiggerWordSize∗ lev(Word1,Word2)
BiggerWordSize
(5.1)
If none of those methods succeed then we can not connect the entry to the UMLS concept.
Even in this case scenario we can proceed to try the ATC and side effect matching, but it will most24
likely achieve no results.
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Once we have the CUI we can do the rest of the name matching sequence with the original26
name and available translations, prioritizing the translations in the same language as the source of
information. This will increase the effectiveness and performance in the matching process.
5.1.6 Drug Evaluation Process 2
Once we have gathered all the possible information available for each drug we will evaluate it
regarding the risk of falling. We can do this evaluation for a single drug in two separated parts. 4
The first part is related to the ATC interpretation. Since the ATC code allows us to verify the drug
types, family and group we will check if that drug is a part of any risk groups and evaluate the 6
inherent risk.
In order to do this we created a subset of ATC codes or parts that might be representing the 8
risk drugs. The other part regards the side effects evaluation. In this part we will check the side
effects that are connected to falls and reach an evaluation based on the number of fall risk side 10
effects.
5.1.6.1 ATC Evaluation 12
In this section we will attribute the ATC code to the drug types listed as risky and explained in
Chapter 2. Each entry to this set will have the related ATC codes and a reference to the article 14
or documents that study and explain the connection to the possibility of falls. The Table 5.8
represents a list of the ATC codes we will take into consideration. 16
Family/Type/Group ATC code
Bezodiazepines N03AE, N05BA, N05CD, N05CF
Antidepressants N06A, N06AX, N06CA
Selective serotonin ruptake inhibitors N06AB
Tricyclic Antidepressants N06AA
Antipsychotics N05A , N05C, N05B
Antiepileptics N03, N03A, N03AX
Central Nervous System (CNS) V09A
Antihypertensives C02
Beta-Blockers C07 , C07A , C07B, C07C, C07D, C07E, C07F
Muscle relaxants M03
Opioids N02A, N01AH
Table 5.8: List of fall related drug families/types/groups
The ATC code from the drug currently being evaluated will be matched or partially matched
to the closest subset of the listed ATC codes. If a match is found we know that the drug is listed 18
as a fall related drug. The level of risk will depend on the match we have found. For example,
we know that Benzodiazepines represent on of the riskier drugs and other drugs like Opioids have 20
some inconclusive studies.
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Each entry in this ATC list have a small description associated that will be displayed if the 22
drug is a match. That small description will explain the reason why the drug is potentially risky
and some additional information.
For example consider the active substance mesoridazin. The ATC code retrieved was N05AC03.2
In the ATC risk subset we can find a partial match with N05A. This will tell us that mesoridazin is
an Antipsychotic drug and that there is a fall risk associated with it. The message associated with4
mesoridazin will be:
N05A -> Antipsychotic drug family This group comprises drugs with antipsychotic6
actions (i.e. neuroleptics)
5.1.6.2 Side Effects Evaluation8
As mentioned before, we can assess the side effects related to a specific chemical substance.
However it is not relevant to our purpose to list all the side effects that may be caused by the usage10
of that substance. In order to study the relevant side effects we conducted a test.
First we tried to find any official and complete document reporting the most common fall re-12
lated side effects, however it was not possible. Nevertheless, we found a document provided by the
Mansfield District Hospital that listed some side effects that we took into consideration[Hos09].14
As an alternative we used a list of fall related drugs. The objective of the test is to evaluate
the recurrence of side effects connected to those drugs. The list of fall related drugs was provided16
by UNC-Chapel Hill news release [Etc08]. In this list we have a total of 93 high risk drugs from
which one of them was not found and eight were not detected as risky by our system. Most of the18
failed detections were due to the Risk ATC not being listed as risky. In the next step we gathered
all the listed side effects on the identified drugs.20
A total of 15 drugs where not listed in the side effects database, so we could not associate their
side effects to this study. We took the side effects with 35+ re-occurrences and studied them in22
order to assess their relationship with falls. We will conduct a more extensive test on the matching
in the Chapter 6 of this document. The reoccurring side effects and the number of recurrences are24
listed in Table 5.9. Note that during the process of side effect identification a total of 78 different
side effects linked to the drugs were found.26
Note that the side effects listed in Table 5.9 are only the ones with 35+ occurrences and that
according to their description may be linked to falls. Side effects like vomiting, nausea, rash and28
some other were not listed since they have no direct connection to falls. We used medicinenet.com
1 to evaluate the side effects type, description and relevance to this case scenario. Medicinenet30
is an online healthcare media publishing company. It provides easy-to-read medical information
for consumers. It is directed by a experienced team of qualified professionals in various fields of32
medicine.
1http://www.medicinenet.com
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Side-effect Number of occurrences
headache 65
hypotension 64
confusion, ataxia,dizziness 62
edema 59
anorexia,syncope 58
tremor 57
hallucinations 56
blurred vision 50
somnolence, euphoria, insomnia 47
weakness, vertigo 46
drowsiness, dyspnea 45
abdominal pain 44
bradycardia, hypertension, hyperkinesia 42
incontinence 41
dystonia, incoordiantion, dyskinesia 40
diplopia, arthralgia 39
asthenia, postural hypotension, photosensitivity, psychosis 38
cramps 37
back pain, urinary frequency 36
peripheral edema 35
Table 5.9: Most common side effects for falls
We gathered a total of 102 side effects that have a clear relation to the fall risk of a medical34
drug. The side effects listed were taken from the study we have conducted and by literature
research [EBM02, RL93, GHG+10, HLL07].
Using our side effects source database we can have access to the side effect’s CUI. This will 2
allow us to do a connection with the side effects in the original ontology population and will avoid
the overlap of existing side effects. 4
Using this method we will list only the relevant side effects for each case.
5.2 Drug-Drug Interaction Evaluation Process 6
To do this kind of evaluation we must do the same drug entry identification process as the one we
do for single drug evaluation. The translations available will increase the possibility of finding a 8
match and consequently the accuracy of the result. As mentioned before we used the DrugDDI
Corpus as a source for the drug-drug interactions. We had to convert the XML source files into a 10
SQLite database. Figure 5.4 represents an example of the original format of the information.
We only took into account the drugs where the Interaction tag was true. From there we only 12
had to link the entity ID to the drug name listed in the XML as well. The Objective of the database
is to contain the names of both drugs and the sentence that relates them. The SQLite structure for 14
the DDI database will be as described in Table 5.10.
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Figure 5.4: XML for a DrugDDI Corpus example
Column Description
Drug1 Drug1 name
Drug2 Drug2 name
Interaction sentence The sentence that explains the interaction
Table 5.10: Drug DDI SQLite Database schema
The database originally contains approximately 3000 drug interactions and a total of 4900 16
chemical substances.
Since the source for this database is created based on InformationExtraction from medical
documents, we have some entries with ambiguous or irrelevant information. For example:2
Drug1 - antihypertensive drugs
Drug2 - hydralazine4
Sentence - When other potent parental antihypertensive drugs, such as diazoxide, are
used in combination with hydralazine, patients should be continuously observed for6
several hours for any excessive fall in blood pressure.
This interaction is not a direct interaction between substances. However it represents more8
than 1 interaction, the interaction between hydrazine and all the drugs that belong to the antihy-
pertensive drug family. In order to solve this ambiguity problem we have to implement a more10
complex solution for the XML interpretation.
Other cases have irrelevant information with entries like "drugs" or "medication" that will not12
help us to get any interaction.
5.2.1 DDI Database Improvement14
To create a more specific and accurate database we will use again the UMLS database to solve
cases like the one previously presented. It is possible for us to get all the substances of a specific16
drug family. With this we can multiply ambiguous entries into chemical substance - chemical
substance interactions. To do this we will use the queries such as the ones show in Listings 5.218
and 5.3.
20
1 Select CUI, LAT, ISPREF, STR
45
Fall Risk Evaluation Process
2 From MRCONSO2
3 Where STR ="Antihypertensive drugs" and ISPREF ="Y";
4 +----------+-----+--------+------------------------+
5 | CUI | LAT | ISPREF | STR | 2
6 +----------+-----+--------+------------------------+
7 | C0003364 | ENG | Y | Antihypertensive Drugs | 4
8 | C0003364 | ENG | Y | antihypertensive drugs |
9 +----------+-----+--------+------------------------+ 6
10 2 rows in set (0.01 sec)
8
Listing 5.2: Concept query
The process represented by Listing 5.2 will get us the identifiers available for the given String
entry. We can use it in the next stage to get the relations between the other concept atoms or 10
translations. The field "ISPREF" refers to preferential terms in use.
12
1 Select CUI1, CUI2, REL, RELA
2 From MRREL 14
3 Where REL="RB" and CUI2 ="C0003364" and RELA ="inverse_isa" and CUI1!="";
4 16
5 AND
6 18
7 select CUI1, CUI2, REL, RELA
8 From MRREL 20
9 Where CUI2 ="C0003364" and RELA ="mapped_from" AND SAB ="MSH";
10 +----------+----------+-----+-------------+ 22
11 | CUI1 | CUI2 | REL | RELA |
12 +----------+----------+-----+-------------+ 24
13 | C0004975 | C0003364 | RB | inverse_isa |
14 ... 26
15 | C2743337 | C0003364 | RB | inverse_isa |
16 | C2936669 | C0003364 | RB | inverse_isa | 28
17 +----------+----------+-----+-------------+
18 120 rows in set (0.04 sec) 30
Listing 5.3: Relation query
As we can see there are two queries in this step represented by Listing 5.3. Only one of them 32
will return results according to the type of relation the substances have with the entry family or
source of information. This happens because UMLS gathers information from several sources and 34
there may be different "RELA" fields that still identify a relation between concepts.
Then we will take all the different CUI’s to check for relations. 36
1 Select CUI, LAT, ISPREF, STR 38
2 From MRCONSO
3 Where CUI="C2743337" and ISPREF ="Y"; 40
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4 +----------+-----+--------+-----------------------------------------------+
5 | CUI | LAT | ISPREF | STR | 42
6 +----------+-----+--------+-----------------------------------------------+
7 | C2743337 | ENG | Y | clonidine, chlorthalidone drug combination |2
8 | C2743337 | ENG | Y | clonidine - chlorthalidone - drug combination |
9 +----------+-----+--------+-----------------------------------------------+4
10 2 rows in set (0.03 sec)
6
Listing 5.4: CUI to concept name
The results returned by the query in Listing 5.4 will be individually analysed since some of
them may need some editing or should not be considered. Listing 5.5 represents a set of possible8
names that can result for the execution of the described process.
10
1 1 - 5-(2-chlorophenyl)-7-fluoro-1,2-dihydro-8-methoxy-3-methylpyrazol(3,4b)(1,4)
benzodiazepine12
2 2 - Alprazolam - chemical (substance)
3 3 - Bromazepam (product)14
4 4 - Methaminodiazepoxide
5 5 - Monopotassium, Clorazepate16
6 6 - N-Descyclopropylmethylprazepam
7 7 - N-Descyclopropylmethylprazepam18
8 8 - N-Descyclopropylmethylprazepam
9 9 - Diazepam [anxiolytic] (product)20
10 10 - acetaminophen + ibuprofen + codeine
22
Listing 5.5: CUI to concept name
In the example result set presented by Listing 5.5 we have some examples of results that need
editing. Elements that are presented in their chemical form as the result number 1 do not need to be24
taken into account, since we will only analyse their chemical substance or brand names. Elements
2, 3, 5 and 9 contain extra information that is irrelevant to our purpose, so they will be edited. We26
can also check duplicated elements like 6, 7 and 8. The result number 10 contains multiple entries
as one String. These entries must be separated and verified individually.28
To analyse and edit the String entries we used he following regular expression (RE) defined in
JAVA:30
(\w\-?\s?\w?)+\s?(\(\w*\))?(\[\w\])?((\[\w*\])\s?(\(\w*\)))?
This will limit the range of results to the ones we want and filter the extra unwanted infor-32
mation. We only limited the more recurrent cases, since it would be impossible to analyse all the
possible scenarios. This RE will limit the entries to strings with simple names or string with both34
normal and straight parenthesis as the ones in line 3, 2 or 9 where we can easily extract the concept
that we want.36
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Note that as we receive the query result for the CUI related with the drug family we will check
the row with most occurrences using the STR field for the comparison. That STR name will be38
the one used to store in the SQLite Drug-Drug interactions database.
We still can limit the languages to English since our interactions database has that language. 2
Using this method we can add several entries to our database based on previous information ex-
tracted from the XML files. 4
It is important to point that an interaction between Drug1 and Drug2 is the same as an inter-
action between Drug2 and Drug1. So, in the query process we must check for both scenarios, 6
since there is nothing that ensuring that the database contains both pairs Drug1-Drug2 and Drug2-
Drug1. 8
To check the accuracy of our drug-drug interactions database we checked for some known
listed drug interactions. This test was done later on and is presented in the Chapter 6. 10
At this point, the information we will need to gather is ready to use. Figure 5.5 presents the
work flow for drug-drug interactions overall evaluation process. 12
Figure 5.5: Overall evaluation process
The work flow starts by evaluating the entries and linking them to the respective drug concepts.
The concepts will allow us to get the entity information we need. The second step represents all the 14
work that is done in the single drug evaluation process. For detailed information on that process
see Figure 5.1. The next step is where we start the real work on the drug interactions. 16
We will verify all the combinations of 2 drugs possible with the entries we have. All those
combinations will be checked for interactions using the DDI database. The interactions will be 18
verified in the given order and in inverse order to assure maximum matching. To improve matching
and since the original source of information has a relatively small number of Database entries we 20
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just load all the entries and match them with the system entries using Levenshtein Distance method
with a NED value of 0,85. 22
As an additional step we can translate the entries and recheck if the original drug is not found.
The possible combination side effects will be presented to the user if any entry was found. The data2
will contain the given drugs with the name of the database entries and the description associated
with them regarding the interaction description.4
5.3 Project Architecture
It is important from the developer’s point of view to know the project layout and Java architecture,6
so here we will explain superficially the project architecture and function of the main parts.
5.3.1 SQLite DrugDB Manager8
This class will be dealing with all SQLite drug database interactions. It works as a handler to help
the other parts of the project, facilitating the communication with the databases. Classes like Drug10
Interaction Manager, MySQL Manager and Side Effects Manager will use this as a gateway to
access, modify or add data.12
5.3.2 Drug Interaction Manager
As the name discloses, this class is responsible for all operations related to the drug-drug Interac-14
tions. It will use all the information presented in the files from the DrugDDI Corpus, organize it
in a structure and pass it to the DrugDB manager to be stored.16
5.3.3 Side Effects TSV Manager
A class similar to the Drug Interaction Manager. It will access and transform the information18
available in the SIDER database files. The original download format of the SIDER datbase is
as 3 TSV files that will be read by this class. In order to get the relations between drugs it will20
cross references between the files to get drug names, side effects and CUI’s that are available on
the records. When the system gets all the information organized it will pass it to the Drug DB22
manager to be stored and ready for usage.
5.3.4 MySQL Manager24
This is an essential part of the project that will be in charge of all the communication with the
UMLS database. All the queries here will be only of the access type since we have no interest in26
edit or add information to the UMLS dataset.
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5.3.5 Project Manager28
The Main class on the project. Here we can access all the information available that was organized
before in the SQLite Databases. A debug interface represented in Figure 5.6 was created to access
all the parts of the project individually that allow for the re-population of the ontology, queries to 2
the SQLite databases, queries to the UMLS database and queries on the ontology itself.
Figure 5.6: System debug menu
5.4 Output Result 4
We intend to have an available web service that will allow the users to query the system and
retrieve a result. The system output allow to user to check the possible consequences of the 6
combination of drugs being used. We can either query for a simple drug evaluation or query for
combinations/interactions results. The system is able to receive an array of multiple drugs and 8
evaluate them both as individuals and as a group for their interactions.
To demonstrate the system output we will use an entry of some risky drugs, combinations, 10
tradenames or chemical substances, and some irrelevant drugs to our goal. We will use Xanax(tradename)
as a fall related drug, Aspirine(tradename) as an irrelevant entry, warfarin and ciprofloxacin to 12
check for drug-drug interactions.
5.4.1 Single drug output 14
Here we will review the part of the result relative to the individual entry drugs evaluation. Since
the result output on the program will, for debug purposes, present the sources and information 16
flow we will only show the output relative to relevant conclusions and data. The Side effects list
will be as well limited and can be consulted in full in the appendix A.1. 18
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Figure 5.7: Xanax system output
As we can see in Figure 5.7, Xanax was correctly evaluated as a trade name of the active
ingredient/substance alprozam. Then it was identified as a member of the benzodiazepines which 20
are one of the main classes related to falls.
Figure 5.8: Aspirine system output
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The second entry in Figure 5.8, Aspirine, was equally identified and evaluated by the system.2
There are some minor situational side effects, but the overall evaluation points to no associated
risk.
Figure 5.9: Verapamilo system output
The concept for verapamilo in Figure 5.9 was found on the ontology population, so the eval- 2
uation was done using that data previously updated with information from the ATC gathered data
and a few added side-effects. The original ontology already had several side effects that should 4
be filtered to the ones related with falls as it is done with data outside the ontology. However, and
aside the vast number of side-effects that can be related to verampil, the drug is not part of a high 6
fall risk drug group.
Figure 5.10: Digoxin system output
As we can see in Figure 5.10, digoxin on its own is not considered risky for falls either. It also 8
presents some side effects that may increase the fall risk associated, however, these side effects
were not retrieved using the original ontology population, but the updated side effects originally 10
from SIDER source database.
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5.4.2 Drug-Drug Interaction output 12
For the 4 entry and since the order is irrelevant there are 6 possible combinations. The system
will identify those 6 combinations and then query the interaction database for any possible entry.
The result will be presented with the names of the 2 drugs and the query result for sentences that2
relates both drug concepts.
Once again, the entire result set for this example is in the appendix A.2 and here we will only4
show in Figure 5.11, one of the interactions and explain some details that might not be obvious to
a non specialist in the field.6
Figure 5.11: Interaction between Xanax and Verapamil
When analysing the first sentence we will not see any direct relation between Xanax and Ver-
apamil, since Xanax is not even in the sentence. However and due to the database disambiguation8
process that we mentioned in Section 5.2.1 we added information relative to terms that represent
a family or a group of substances. In this case, Xanax is a tradename of Alprozam that is men-10
tioned in the text. There are several cases where this happens during the identification of drug
interactions.12
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Chapter 6
Result Analysis14
This analysis will be conducted in order to study the process of re-population/update of our data2
model and to evaluate the accuracy of the system response. To do this we will at first check the
entries of the original ontology population that we were able to identify and update with new fall4
related information. To check if this process was conducted with loss of information due to miss
match between the original ontology population and our sources we will do a match evaluation.6
As the second phase of the evaluation we will use available lists of drug-drug interactions and
fall risk medication to access the veracity of the result given by this thesis system. This is an8
overall system evaluation and will use verified information in the field based news/articles/studies.
6.1 Update of the original data model population10
Here we will conduct a simple test regarding the effectiveness of linkage between the various
information sources we will need. The objective is to use the original ontology population and12
conduct a study that will retrieve a matching ratio and complete the updated data model with new
information. Ideally all the entries of the original population would be found, however, that result14
is unlikely since the original population contains some entries that may not be considered exactly
medical drugs or simply are not found in our databases. Those cases will be explained in detail16
later on this Chapter. Anyhow, the system sources regarding the chemical substances and entities
are extensive and reliable, so we have good matching perspectives and consequently the update of18
the ontology model should be complete.
To conduct the tests we developed an extra class in the project architecture called Match-20
ingTestClass that is responsible for all the matching and checking tests.
6.1.1 Concept identifying process22
In order to get a great part of the information we need a link between the original population and
the UMLS Database. To check if that link is done properly we developed this test/verification.24
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The UMLS is the most complete database we have at our disposal, so we hope to achieve a high
match ratio for this verification. Firstly we decided to match the concepts using only the SQLite26
subsets. The process will prioritize the SQLite PT subset, then the SPA subset and at last the ENG
subset. We obtained the results shown in Table 6.1. 2
Subset Matches Total Remaining Match Ratio
POR 530 1359 39%
SPA 327 829 39,44%
ENG 42 502 8,36%
Total 899 1359 66,15%
Table 6.1: Concept matching results
Note that the verification to the Spanish subset does not contain the concepts already found in
the Portuguese search. The same thing happens in the English subset. 4
Using only subset information we were able to link 66,15% of the total entities available in the
ontology. However, to increase this number we will submit the remaining entries to a search using 6
UMLS MySQL complete database. The results retrived from this study are presented in Table 6.2.
Database Matches Total remaining Match Ratio
UMLS 97 405 24%
Absolute total 966 1359 73%
Table 6.2: UMLS concept matching results
The majority of non-match entries are due to no CUI entry because they are not considered ac- 8
tual chemical substances, no translation available or minor name differences in the UMLS database
where we can not apply the Levenshtein Distance method in the query. 10
6.1.2 ATC linkage process
This evaluation will be made according to the steps used in the re-population algorithm. We will 12
check all the different entries in the original ontology set. This means that we have to divide the
composed entries and check for duplicates. After the definitive list of entries is ready we will 14
check for the translations using UMLS subsets to match with the ATC sources. If a direct match
is not possible with the translation and ATC entries we will try a Levenshtein Distance match with 16
a NED value of 0,85.
The direct matching algorithm without translation obtained the results shown in Table 6.3. The 18
results are base on the original ontology population with a total of 1359 different concepts.
Since this first part of the ATC matching analysis only uses direct matching the low ratio may 20
be considered normal due to the limitation in the databases to 2 languages and no checking in the
translations. Using the SQLite database to check for translation improved result were achieved. 22
The data on those results are presented in Table 6.4.
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SQLite Source Matches Match Ratio
ATC ENG 185 13,6%
ATC GER 265 19,5%
Both 182 13,5%
ATC Total 268 19,7%
Table 6.3: ATC direct match results
Source Matches Total translated Match Ratio
ATC ENG 676 857 78,87%
ATC GER 520 857 60,68%
Table 6.4: ATC direct match results with translation
A total of 857 entities refers to the entries that had CUI and we could translate. As it is proved 24
by the results the matching ratio increased immensely when we search for concepts using the same
input language. Nevertheless, these results can still be improved and we have to find a method to
apply to the concepts with no translation.2
In many translations the only thing that will differ from one language to another is the last
character, accentuation or a different character. This problem can be easily solved. To do this we4
conducted the following matching improved with Levenshtein distance in the concepts without
CUI and in the concepts that still had no match, a total of 574 entries, as presented in Table 6.5.6
Source Matches Total Translated Match Ratio
ATC ENG 169 574 29,4%
ATC GER 84 574 14,5%
Table 6.5: ATC improved match results
Since all the results we found in ATC_GER are also found in ATC_ENG we do not have any
overlap and with these last improvements we reached a total and final match ratio of 70,2% verified8
in the algorithm and explained by the equations 6.1 and 6.2.
TotalPopulation− (Remaining−newMatch) = TotalMatch (6.1)
Where we apply the values:10
1359− (574−169) = 954 (6.2)
The remaining 30% drugs will have to be evaluated based only on the side effects associated
with them. After all the efforts to improve the matching result we think that the only way to12
improve even more the data association is by using a more complete ATC source.
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6.1.3 Side effects update14
The evaluation of side effects entries will be done according to the same principles used on the
ATC evaluation. We will check for direct matches between the names in the original data model
population and if with that match it is not possible we will try a match using Levenshtein Distance 2
with the same NED value of 0,85.
The direct results of this methods are shown in Table 6.6. 4
Operation Result Total
Matched 590 1359
Not matched 768 1359
Not Translated 460 1359
Table 6.6: Side Effects matching results
There were some entries where even without translation we managed to have a match using the
Levenshtein Distance. However, there are still several concepts without translation. We decided 6
to conduct a more extensive test to find out why this was happening.
On the total of 768 entries that were not found, 371 were not even accessible via UMLS 8
database, the most complete database we had access to. The reason for this is simple after checking
some of the entries that were not found: 10
• brometo declidinio
• pidolato de calcio 12
• 0.12 mg/24 hnuvaring1 unid
• Tintura de Bendoim 14
• Sais Minerais
• vacina contra hepatite C 16
• vacina contra a difteria, o tetano,a tosse convulsa e o haemophilustipo b
Some concepts were not identified because they were wrongly recorded in the data model 18
during the extraction process like brometo declidinio, 0.12 mg/24 hnuvaring1 unid; or cloreto
depotassio. Some of these cases could be solved with Levenshtein Distance, but if the source for 20
the concept was the UMLS MySQL database we can not apply a direct query using that method.
Some other concepts may be easily recognisable by a professional, but they are on record with 22
a non-scientific or non appropriate nomenclature, therefore the entry in the UMLS dataset may not
exist. Examples like Sais Minerais and Tintura de Bendoim can reflect those cases. 24
Another reason for those mismatches is the vague concept listed in the entry name. Examples
of these cases like vacina contra hepatite C or vacina contra a difteria, o tetano,a tosse convulsa 26
e o haemophilustipo b. The list of all these 371 concepts is available in the Appendix A.3.
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The remaining 397 entries that had translation but still had no match on the side effects 28
database simply were not listed in the source.
Most of the errors presented here are normal since the original ontology population was all cre-
ated using Information extraction. However, with the translation and concept identifying system2
we used we were able to minimize the mismatches in the model population.
6.1.4 Drug interactions4
As mentioned before, in this part of the system we will add a direct interaction relation between
the concepts if they both exist in the ontology. Otherwise, if only one of the drugs exists in the6
original model population we will add a Data property identifying the name of the interacting drug
and the respective CUI. If none of the drugs exists in the dataset we will not add anything.8
In this test we will evaluate the concept linkage between the original population ontology and
our improved interaction database. Table 6.7 present the results obtained.10
Operation Result Total
Matched 479 1359
Not matched 880 1359
Table 6.7: Ontology concept linkage to the DDI database
As we can see, based on these results, the matching ratio we achieved is not optimal. This fact
can be justified since the ontology population and the Drug DDI population are both extracted and12
created using Information Extraction from documents and are not optimal for this kind of usage.
The accumulation of possible extraction errors from both parts causes a decrease in the matching14
ratio. We tried to improve this match ratio during the Interaction database improvement process
by expanding the concepts and by using approximated string matches (Levenshtein Distance),16
however, in order to achieve a more accurate result the best approach is the utilization of another
source for drug-drug interactions.18
6.2 Result accuracy evaluation
This section’s objective is to evaluate the overall results obtained by the system. It intends to check20
if the retrieved results are in fact correct. To do this we will use a set of drugs listed by an official
document and manually checked out by healthcare professionalsA.4. The existing drugs on the22
document will be fed to the system and hopefully it will identify them and their drug family as
risk related.24
The other part of this evaluation will be about the interactions. To assess the accuracy here we
will use again verified data and compare the verified results to this system’s results.26
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6.2.1 Single drug
To do this evaluation we used a list of drugs that are considered risky for falls from UNC-Chapel28
Hill news [Etc08]. This list contains a total of 93 drug entries with trade names and chemical
substances. It can be consulted in the appendix A.4 of this document. 2
A total of 83 Drug entries were correctly identified as risky based on the ATC match. The 10
remaining entries were not identified as risky for various reasons. Table 6.8 shows the details on 4
the remaining substances and we will suggest how the results could be improved.
Substance CUI ATC Side-effects
Oxymorphone X - -
Levorphanol X - -
Butabarbital X - -
Clidinium-chlordiazepoxide - - -
Codeine X R05DA04 X
Digoxin X C01AA05 X
Disopyramide X C01BA03 -
Divalproex sodium X - -
Hydrocodone X R05DA03 -
Duloxetine X G04BX18 X
Table 6.8: Accuracy results
As we can see, the majority of the drug entries were identified and related to the respective 6
concepts in the UMLS database. However, only half of the concepts were successfully connected
to the ATC entry. This problem alone represents a big problem in the evaluation process, how- 8
ever, we can not do anything about these specific cases since we are limited to the ATC database
information available to us. 10
Another problem verified in 4 out of 10 concepts was the identification of the ATC as not
risky. This happens because these specific drugs represent exceptions. The drug family/type of 12
this drugs are not linked to any increase in the fall ratio. However, these specific drugs are, so,
what we can do is add the CUI relative to this specific substance as risky. Adding the substance 14
family or sub-family to the risky ATCs would be a mistake once it would falsely assess several
substances as risky. 16
The overall result of this test point to a correct identification of 83 out of 93 substances as
risky. This represents a success ratio of 89,25%. A concept identification ratio of 98,89% leaving 18
only Clidinium-chlordiazepoxide unlinked and an ATC identification ratio of 94,62%.
6.2.2 Interaction study 20
Here we will need to develop a similar method as the one used in the fall evaluation for Single
drug. To do this the first step we have to accomplish is to find a viable list of interactions in order 22
to check the quantity and quality of our database information. As we mentioned before, in this
case our source dataset was not ideal due to the quantity of information and generation method. 24
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Anyhow we expect it to have a decent performance since we worked on the database improvement.
We did not add any data manually, so all the extra information was created using inference. The 26
process is explained in Section 5.2.1.
For result comparison purposes we used a list of 10 drug interaction for long term patients by2
SeniorJournal.com 1.
• Warfarin — NSAIDs 24
• Warfarin — Sulfa drugs
• Warfarin — Macrolides6
• Warfarin — Quinolones 3
• Warfarin — Phenytoin8
• ACE inhibitors — Potassium supplements
• ACE inhibitors — Spironolactone10
• Digoxin — Amiodarone
• Digoxin — Verapamil12
• Theophylline — Quinolones 3
As we can see this scenario is more complex than a simple database query since we have first14
to check for non chemical substance concepts like Quinolones or NSAIDs.
We used the search algorithm and obtained the Table 6.9:16
Drug1 Drug2 Interaction entries
Warfarin NSAIDs 27
Warfarin Sulfa drugs 0
Warfarin Macrolides 0
Warfarin Quinolones 11
Warfarin Phenytoin 20
ACE inhibitors Potassium 5
ACE inhibitors Spironolactone 0
Digoxin Amiodarone 1
Digoxin Verapamil 2
Theophylline Quinolones 5
Table 6.9: Interactions Results
As verified, only 3 of the 10 entries did not receive any query result. The entries were checked
to see if they are a generalist concept and expanded into the concept components. If they still18
1http://seniorjournal.com/NEWS/Eldercare/4-12-14TenDrugs.htm
2NSAID class does not include COX-2 inhibitors
3Quinolones that interact include: ciprofloxacin, enoxacin, norfloxacin and ofloxacin
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have no result that means that our source did not contain any relevant information to the given
combination. To check this we searched manually for drug interactions between substances of the20
families that were not matched and got no results as expected.
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Conclusion
After all the work developed during this project it is important to review the process and identify2
flaws and mistakes in order to improve future work. In this section we will overview the last
months of work and point some problems that were identified and the perspectives of solution4
to those problems. We will also talk about imperfections of this tool that can be corrected and
improved in the future.6
7.1 Objectives overview
In this section we will evaluate the fulfilment of the proposed objectives. The project turned out8
to be slightly different from what i was initially anticipating with a lot of work regarding concepts
and information linkage. The knowledge representation model was indeed a very important part10
of the system, responsible for the storage and organization of all information.
The main objective of this dissertation is the evaluation of the impact of single and multi drug12
usage on falls in the elderly population. To do this several objectives were outlined in Chapter 1.
We started by developing an updated model of the existing knowledge representation model14
that would be capable of representing the medicine and the development of an algorithm capable
of reaching conclusions on the side effects of multiple medications. The system should be capable16
of identifying drug entries representing chemical substances or drug trade names.
Later on the entries should be related to the respective concept or entity in the data model so18
they can be analysed properly. If the entry represents a trade name the system should also be able to
retrieve the respective chemical substance to evaluation purposes. After having the concept name20
and substances identified the system should access the related side effects, drug class classification
and make a fall risk evaluation for a single drug or combination of drugs.22
The currently updated ontology model is capable of representing all the concepts related to the
medication needed for our algorithm in order to evaluate the fall risk. It still contains data from24
the original model that is not used during the evaluation, however it makes no sense to remove
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those parts of the ontology since it will allow the usage of the ontology for other purposes and is26
no obstacle to our objective.
The ontology population update process was as well successfully implemented. Using the
external sources, the system checks and identifies the concepts, linking them to the entries existing 2
in the external sources. Once this linkage is done, the process continues and new information is
added to the model. 4
The final objective, the evaluation of fall risk, was as well fulfilled with good results and using
all the data from the previously named objectives. 6
7.2 Conclusion
The usage of medical electronic systems, digital information records and decision support systems 8
are becoming in the current days more and more frequent. They represent a way to improve the
health system with a small cost. This dissertation intends to use the available digital records about 10
the drugs and create a tool that can help using and analysing that information to identify possible
falls risks for single drug and drug combinations in elder persons. 12
Overall, the result we achieved in this project were a success. Using known sets of drugs that
have already been proven to have a relation to the falls in older people, we managed to test our 14
system qualitatively and quantitatively. The success ratio in this tests were 90% for single drugs
and 70% for drug-drug interactions. 16
In conclusion, the development of a system with an entire work flow, where we have drug
identification, concept association and evaluation, was executed. 18
The system can be used in collaboration with several projects aiming for the study and pre-
vention of falls. The basic interaction process with external medical sources can also be used to 20
achieve other search or evaluation processes in the medical/pharmaceutical field.
7.3 Improvements and future work 22
After gaining some experience in the field and knowledge of the problem and the project there are
a few things that should have been done differently. First of all the usage of the UMLS language 24
subsets. It is in fact a faster query process for the translation process, even so, the gain is not
substantial, the work time used to create the databases was significant and we still need to use the 26
UMLS MySQL database to do queries that are not related to the translation process. The subsets
were created in a first stage of the system development where we did not predict the need for some 28
other queries to the UMLS database.
A substantial improvement to the project would be the introduction of a more complete and ac- 30
curate interactions database, since the current one was developed out of a corpus with a completely
different objective than the one we have here. 32
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The matching process was improved regularly during the development of the project, however,
there still is room for more improvements by matching accuracy and quantity or even by perfor- 34
mance. This last factor was taken into account and greatly improved during the project but not the
focus of our attention since it represents a secondary goal, being the priority the effectiveness of2
the system.
Associação Fraunhofer Portugal intends to use the work developed during this thesis and im-4
prove it to be used as a part of other fall related projects currently under development.
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Appendix
A.1 Single drug evaluation Output
2
The drug Xanax has not been found in the ontology.
trying to check the drug on SQLite databases...4
Connecting to Database: jdbc:mysql://localhost/UMLS to check if it is tradename6
CUI found: C0699034
Xanax is a tradename8
Connecting to Database: jdbc:mysql://localhost/UMLS to get Active substance!10
CUI found: C0699034
Identifyed active substance: alprazolam12
CUI: [C0002333, liteUMLSPT]
Trying ATC for: Alprazolam14
[N, 05, B, A, 12]
Name: [alprazolam]16
CUI: [C0002333, liteUMLSPT]
ATC: [N, 05, B, A, 12]18
SideEffects:
back pain - C000460420
diplopia - C0012569
feeling drunk - C052217222
confusion - C0009676
incontinence - C002116724
anorexia - C0003123
dystonia - C039359326
incoordination - C0520966
blurred vision - C034423228
somnolence - C2830004
edema - C001360430
ataxia - C0004134
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weakness - C188355232
asthenia - C0004093
vertigo - C0042571
muscle stiffness - C0221170 2
tremor - C0040822
muscle weakness - C0151786 4
dyskinesia - C0013384
Cognitive Disorder - C0009241 6
peripheral edema - C0085649
cramps - C0026821 8
drowsiness - C0013144
hallucinations - C0018524 10
euphoria - C0235146
abdominal pain - C0000737 12
Mental impairment - C1306341
insomnia - C0917801 14
stiffness - C0427008
arthralgia - C0003862 16
hypotension - C0020649
headache - C0018681 18
The drug alprazolam with the ATC Code N05BA12 is a risk drug with the following message:20
N05BA -> Benzodiazepine derivative with high fall risk
This group comprises preparations used in the treatment of neuroses and psychosomatic disorders associated with anxiety and tension, e.g. benzodiazepines.22
--------------------------------------------------------------------------------------------------------------24
The drug Aspirine has not been found in the ontology.
trying to check the drug on SQLite databases... 26
Connecting to Database: jdbc:mysql://localhost/UMLS to check if it is tradename28
No CUI FOUND
Aspirine was not identifyed as a tradename! 30
CUI: []
NO CUI FOUND IN SQLITE DATABASES! 32
Trying UMLS Database...
Trying ATC for: Aspirina 34
[A, 01, A, D, 05]
Name: [Aspirine] 36
CUI: [C0004057, UMLS]
ATC: [A, 01, A, D, 05] 38
SideEffects:
edema - C0013604 40
vertigo - C0042571
confusion - C0009676 42
drowsiness - C0013144
68
Appendix
44
Given ATC, [A, 01, A, D, 05] is not taged as risky.
--------------------------------------------------------------------------------------------------------------2
Drug verapamilo listed from the ontology records:
4
Drug Name: VERAPAMILO
Drug Cui: C00425236
ATC: C08DA01
Chapter: 3.4.3.8
Side Effects:
abnormal vision - C004279810
increased sweating - C0700590
hiperplasia gengival - c001756612
Symptoms of hepatitis - C0858814
flushing - C001638214
sinus arrest - C0178428
Sinusite - c003719916
paralisia intestinal - c0030446
paralysis - C052222418
Icterícia - c0022346
fraqueza muscular - c015178620
edema periférico - c0085649
dor torácica - c000803122
dor torácica - c0030193 c0004757
macula - C033257324
Fadiga - c0015672
hypertrophic subaortic stenosis - C070005326
dissociation - C0086168
extrapyramidal syndrome - C001537128
upper respiratory tract infection - C0041912
polaquiúria - c004202330
keratosis - C0022593
dores articulares - c000386232
palpitações - c0030252
síncope - c003907034
enlargement - C0020564
xerostomia pós-irradiação - c0043352 pós-irradiação36
numbness of extremities - C0239375
desconforto abdominal - c023248738
sinais extrapiramidais - c0234133
rinite - c003545540
Vasculite - c0042384
Bloqueios auriculoventriculares - c000424542
ileus - C1258215
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respiratory failure - C114567044
Urticária - c0042109
edema dos tornozelos - c0235439
somnolence - C2830004 2
faringite - c0031350
parestesias - c0030554 4
trémulo - c0392703
colestase - c0008370 6
quadriparesis - C0270790
hypertrophic cardiomyopathy - C0007194 8
Obstipação - c0009806
laryngospasm - C0023066 10
causar hipotensão ortostática associada a tonturas - c0085978 c0020651 c1608982 c0012833
hiperplasia - c0020507 12
mal-estar gastrintestinal - c0234215 gastrintestinal
seizures - C0036572 14
gastrointestinal distress - C0548823
eritema polimorfo - c0014742 16
desequilíbrios hidroelectrolíticos - c0281825 hidroelectrolíticos
Alopécia - c0002170 18
reacções de hipersensibilidade com choque - c0020517 c0036974
tratamento da disfunção eréctil - c0039796 c0242350 20
diplopia - c0012569
mialgias - c0231528 22
ginecomastia - c0018418
dermatoses hiperqueratósicas - c0037274 c0870082 24
complete atrioventricular block - C0151517
Vertigem de causa - c0042571 c0085978 26
maculopapular rash - C0423791
Edema ligeiros - c0013604 ligeiros 28
broncospasmo passageiro - c0006266 passageiro
edema pulmonar - c0034063 30
surgir ainda dispneia ainda - c1948041 c0013404 ainda
Hepatite B em doentes com infecção - c0019158 c0004690 c0030705 c0021311 32
weakness - C1883552
ECG abnormal - C0522055 34
ecchymosis - C0013491
angioedema - c0002994 36
casos de eritema com sintomas - c1053418 c0041834 c0683368
cardiomiopatia - c0878544 38
sinais de intoxicação incluem visão turva - c0220912 c0728899 c0344232
Astenia - c0004093 40
coldness - C0812387
prolactin increased - C0553731 42
claudication - C1456822
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Dispepsia - c0013395 44
oligomenorreia - c0028949
hiperprolactinemia - c0020514
hypertensive - C08571212
Tratamento de sintomas depressivos - c0039796 c0086132
Alterações do sono - c00373174
tratamento de infecções respiratórias - c0039796 c0021311 respiratórias
tratamento de infecções respiratórias - c0039796 c0039796 c00352436
púrpura - c0034150
diárias - c00119918
confusão mental - c0009676
sulfonamida incluem erupção cutânea - c0038760 c001523010
dor associada ao enfarte do miocárdio - c0030193 c1608982 c0027051
gripe - c002140012
atrioventricular dissociation - C0004331
elevated liver enzymes - C023599614
acidente vascular cerebral - c0038454 c0238051
allergy aggravated - C023589316
casos descritos de galactorreia - c1053418 c0038545 c0235660
tinea cruris - c0040264 cruris18
tinea cruris - C1384589
controlo das náuseas - c0243148 c002749720
prurido das alergias cutâneas - c0033774 c0020517 cutâneas
sudorese - c003899022
cãibras - c0026821
Cefaleias - c001868124
nistagmo - c0028738
numbness - C002864326
SNC incluíndo insónia - c0927232 c0917801
tratamento de doentes com infecção - c0039796 c0030705 c002131128
choque anafiláctico - c0002792
drowsiness - C001314430
tremor - c0040822
vómitos post-operatórios - c0042963 post-operatórios32
Letargia - c0023380
dor ligeira - c0030193 ligeira34
prevenção de espasmos - c0199176 c0037763
muscle fatigue - C024297936
IC congestiva - c0018801 congestiva
Given ATC, [C, 08, D, A, 01] is not taged as risky.38
--------------------------------------------------------------------------------------------------------------
The drug Digoxin has not been found in the ontology.40
trying to check the drug on SQLite databases...
42
Connecting to Database: jdbc:mysql://localhost/UMLS to check if it is tradename
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CUI found: C001226544
Digoxin was not identifyed as a tradename!
CUI: [C0012265, liteUMLSPA]
Trying ATC for: Digoxina 2
[C, 01, A, A, 05]
Name: [Digoxin] 4
CUI: [C0012265, liteUMLSPA]
ATC: [C, 01, A, A, 05] 6
SideEffects:
dizziness - C0012833 8
confusion - C0009676
hallucinations - C0018524 10
abdominal pain - C0000737
weakness - C1883552 12
visual disturbances - C0547030
psychosis - C0033975 14
anorexia - C0003123
bradycardia - C0428977 16
headache - C0018681
18
Given ATC, [C, 01, A, A, 05] is not taged as risky.
20
--------------------------------------------------------------------------------------------------------------
22
A.2 Drug-Drug Interaction output
------ --------- -------- 24
Interaction for Xanax and verapamil
26
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.28
------ --------- --------
Interaction for Xanax and Digoxin 30
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.32
Digoxin Some calcium blockers may increase the concentration of digitalis preparations in the blood.
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.34
------ --------- --------
Interaction for Aspirine and verapamil 36
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.38
In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
------ --------- -------- 40
Interaction for Aspirine and Digoxin
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Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
Digoxin Some calcium blockers may increase the concentration of digitalis preparations in the blood.
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.2
------ --------- --------
Interaction for verapamil and Digoxin4
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.6
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
Digoxin Some calcium blockers may increase the concentration of digitalis preparations in the blood.8
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
A.3 Side Effects not matched10
CUI FOUND:397 NOT CUI FOUND:371
levofolinato de calcio12
brivudina
brometo de ipratropio14
alfatocoferol
vacina contra a hepatite b16
fenspirida
oleo essencial de tomilho18
tintura de benjoim
tintura deeucalipto20
maca reineta
nicotinato de benzilo22
pirissudanol
peginterferao alfa-2b24
prulifloxacina
oxibuprocaina26
propinoxato
multivitaminas28
sais minerais
dalteparina sodica30
bromelaina
brometo de ipratropio32
lutropina alfa
acido hialuronico34
multivitaminas
nimesulida36
vitaminas do complexo b
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acidoascorbico38
carbonato de di-hidroxidodealuminio e sodio
polistireno sulfonato de calcio
celulas vivas de levedura 2
oleode figado de tubarao
vacina contra o meningococo 4
oxido de zinco
dioxido de titanio 6
hamamelia
cloro-hexidina 8
interferao beta-1b
glicerofosfato demagnesio 10
messalazina
sulodexida 12
vacina contra a difteria e omeningococo
acetonido de fluocinolona 14
subgalhatode bismuto
clorotalidona 16
cafeina
aminoacidos 18
vacina viva contra o rotavirus
peroxido debenzoilo 20
rupatadina
vinpocetina 22
carmelose
clorodiazepoxido 24
sulbutiamina
acetilsalicilato de lisina 26
folitropina alfa
fosfato tricalcico 28
proglumetacina
salicilato demetilo e outras associacoes 30
acido borico
hidroxido de aluminio 32
carbomero
ebastina 34
aceglumato de deanol
mononitrato de isossorbida 36
galium molugo
propifenazona 38
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cafeina
fondaparinux sodico 40
fluoreto de sodio
fluorofosfato de sodio2
vacina contra a hepatite a e ahepatite b
nonivamida4
benzilpenicilina potassica
polisulfato sodico de pentosano6
azuleno
vacina contra a difteria, o tetanoe a tosse convulsa8
sais minerais e outrasassociacoes
acetato de calcio10
acido ibandronico
levodropropizina12
beladona (alcaloides)
cloreto decetilpiridinio14
alcool diclorobenzilico
“heparinoide”16
aceponato de metilprednisolona
para-diclorobenzeno18
acido cromoglicico
etofenamato20
hidroxido de magnesio
vacina contra o haemophilus tipo b22
acetato de calcio
carbonato demagnesio24
anacinra
cloreto de zinco26
mirtecaina
butilescopolamina28
peroxido de hidrogenio
carbonato de di-hidroxidodealuminio e sodio30
clonixina
indobufeno32
acido nicotinico
interferao gama-1b34
alcatrao mineral
piritiona dezinco e outras associacoes36
imunoglobulina humana contra ocitomegalovirus
cloreto de sodio38
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cloreto de potassio
glucoronamida40
risedronato de sodio
plantago ovata (sementes) 2
hidrosmina
macrogol e outras associacoes 4
vacina pneumococica poliosidica
acetato de eslicarbazepina 6
deflazacorte
tetrizolina 8
acido lactico
lecitina de soja 10
oleo de soja
clorotalidona 12
mesilato de di-hidroergocriptina
cefodizima sodica 14
iodeto de tibezonio
lisado de escherichia coli 16
vitaminas do complexo b
trepibutona 18
tolterrodina
salicilato demetilo 20
oxibuprocaina
proteinosuccinilato de ferro 22
butamirato
aliscireno 24
cobamamida
brometo de pinaverio 26
promestrieno
picetoprofeno 28
oxolamina
sevelamero 30
oxido de zinco
rilmenidina 32
lisados polibacterianos
oleo essencial de eucalipto 34
oleoessencial de terebintina
acetonido de fluocinolona 36
iodopovidona
difluocortolona 38
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brometo de tiotropio
cinchocaina 40
tiocolquicosido
hidrogenofosfato de calcio2
insulina aspartico
tri-hexifenidilo4
cleboprida
palonossetrom6
citrato de potassio
lactobacillusacidophilus8
cetrorrelix
diacereina10
acido lactico
sabalserulata12
citrato de potassio
peginterferao alfa-2a14
mesilato de di-hidroergotamina
piritiona zinco16
picossulfato de sodio
brometo de domifeno18
tribenosido
ciamemazina20
tromantadina
buserrelina22
cloreto dedequalinio
factor viii da coagulacao humana24
peroxido de benzoilo
interferao alfa-2a26
mesilato de di-hidroergocristina
dicloverina28
fosfato dissodico
fosfatomonossodico30
pangamato de calcio
hidroxido de aluminio32
hidroxidode magnesio
tansulosina34
peroxido de benzoilo
fenolftaleina e outrasassociacoes36
laurilsulfoacetato de sodio
nadifloxacina38
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ustecinumab
valerato deestradiol40
carboximaltose ferrica
cromocarbo dietilamina 2
benzilpenicilina procainica
dapoxetina 4
acidosalicilico
mirtecaina 6
cloreto de sodio
flupirtina 8
hipericao
colecalciferole 10
sais minerais
fluoreto de sodio 12
agomelatina
oleo de soja 14
etofibrato
ruscogenina 16
nilvadipina
brometo de distigmina 18
sulfadiazina prata
”heparinoide” 20
insulina isofanica
ictiol 22
oleo de soja
di-hexazina407 24
cloreto de zinco
cloro-hexidina 26
cloreto de trospio
clorofenoxamina- 28
hidrolisado cerebral de porco
ictiol 30
lecitina desoja
ispagula (tegumento) 32
ispagula(semente)
oxitriptano 34
pidolato de magnesio
dectafluor 36
fluoreto de sodio
olafluor 38
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valeratode estradiol
cloreto debenzalconio 40
acido ursodesoxicolico
lactogluconato de calcio2
para-aminobenzoatode magnesio
hipromelose4
complexo hidroxido ferrico-polimaltose
acido alendronico6
cloromadinona
colquicina8
zafirlucaste
dropropizina10
policresaleno
alcool isopropilico12
alcoolpropilico
etilsulfato demecetronio14
acido nicotinico
etonogestrel0.015 mg/24 h16
0.12 mg/24 hnuvaring1 unid;
acido espaglumico18
clorodiazepoxido
brometo declidinio20
butilescopolamina
pidolato de calcio22
bicarbonatode sodio
imunoglobulina humana contra avaricela24
imunoglobulina humana normal
cloreto de calcio26
cloreto depotassio
cloreto de sodio28
heparina sodica
oxerrutinas30
lisado de colibacilos
benzilpenicilina benzatinica32
benzilpenicilina potassica
cloreto de calcio34
dexcetoprofeno
interferao alfa-2b36
cetazolam
alcooldiclorobenzilico38
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acido alginico
acido estearico40
erisimo officinalis
montelucaste 2
cloperastina
acido lactico 4
bromoprida
vacina contra a difteria, o tetano,a tosse convulsa e o haemophilustipo b 6
reviparina sodica
hidroxiquinolina 8
folitropina alfa
lutropina alfa 10
esteres etilicos 90 do acidoomega-3
vinburnina 12
aspartato de arginina
flubendazol 14
vaccinium myrtillus(antocianosidos)
cloreto de dequalinio 16
cinchocaina
omoconazol 18
toxina botulinica a
carbonatode magnesio 20
pirenoxina
tiropramida 22
vacina contra a hepatite a
vacina contra o papilomavirushumano 24
isobenzidrina
polistireno sulfonato de sodio 26
gonadotropina corionica
secnidazol 28
nicotinato de alfatocoferol
cassia angustifolia (fruto) 30
ispagula (mucilagem)
plantagoovata (sementes) 32
vacina viva contra o sarampo
cloreto de benzalconio 34
agua de hamamelis
aliscireno 36
vacina contra a gripe
vacina inactivada contra aencefalite provocada por picadade carraca 38
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foliculina
carbonato de lantanio 40
hidroxiapatite
difluocortolona2
vacina adsorvida pneumococicapoliosidica conjugada
complexo hidroxidoferrico-polimaltose4
tansulosina
insulinaisofanica6
parnaparina sodica
metamizol magnesico8
interferao beta-1a
cobamamida10
acetato de glatiramero
amissulprida12
policresuleno
acido alendronico14
valproato semisodico
micofenolato de mofetil16
colagenase
acido quenodesoxicolico18
alcatrao mineral
“heparinoide”20
clorazepato dipotassico
aminaftona22
calcitonina de salmao
acido para-aminossalicilico24
tropissetrom
heparina sodica26
salicilato dedietilamina
tiocolquicosido28
imunoglobulina humana contra ahepatite b
altizida30
clorofenoxamina
benzoato de benzilo32
tinzaparina sodica
oleo essencial de hortela pimenta34
cloreto de magnesio
cloretode potassio36
levotiroxina sodica
enoxaparina sodica38
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acido dimecrotico
carbasalato calcico40
salicilato demetilo
pepsinae outras associacoes 2
brometo de otilonio
senosido a 4
senosido b
octreotido 6
tianeptina
alfatocoferol 8
acidoascorbico
acido zoledronico 10
extracto de camomila
gluco-heptonatodecalcio 12
promestrieno
acido borico 14
oxido de zinco e outrasassociacoes
sene e outrasassociacoes 16
aspartatode potassio
cloreto de cetilpiridinio 18
mesoglicano sodico
cafeina 20
vacina viva contra a varicela
acido azelaico 22
loflazepato de etilo
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A.4 UNC-Chapel Hill drug list 24
83
Prescription medications that increase the risk of falls for patients 65 and older 
Related UNC-Chapel Hill news release: http://uncnews.unc.edu/news/health-and-medicine/some-
drugs-increase-risk-of-falling-unc-researchers.html 
 
Generic Name (Brand Name) 
 
Alprazolam (Xanax)  
Amitriptyline (Elavil) 
Amobarbital (Amytal) 
Amoxapine (Asendin) 
Aripiprazole (Abilify) 
Baclofen (Lioresal) 
Bupropion (Wellbutrin, 
Wellbutrin SR) 
Buspirone (Buspar)  
Butabarbital 
Carbamazepine (Tegretol, 
Tegretol XR, Carbatrol) 
Chloral hydrate 
Chlorazepate (Tranxene) 
Chlordiazepoxide (Librium, 
Limbitrol, Librax) 
Chlorpromazine (Thorazine) 
Citalopram (Celexa) 
Clidinium-chlordiazepoxide 
(Librax) 
Clomipramine (Anafranil) 
Clonazepam (Klonopin)  
Clozapine (Clozaril) 
Codeine (Tylenol with Codeine) 
Desipramine (Norpramin) 
Diazepam (Valium) 
Digoxin (Lanoxin) 
Disopyramide (Norpace) 
Divalproex sodium (Depakote, 
Depakote ER) 
Doxepin (Sinequan, Zonalon, 
Prudoxin) 
Duloxetine (Cymbalta) 
Escitalopram (Lexapro) 
Estazolam (Prosom) 
Olanzapine (Zyprexa, Zyprexa 
Zydis) 
Oxazepam (Serax)  
Oxcarbazepine (Trileptal) 
Oxycodone (Percocet) 
Oxymorphone (Numorphan) 
Paraldehyde (Paral) 
Paroxetine (Paxil) 
Pentobarbital (Nembutal) 
Perphenazine (Trilafon) 
Phenelzine (Nardil) 
Phenobarbital 
Phenytoin (Dilantin) 
Pimozide (Orap) 
Pregabalin (Lyrica)  
Primidone (Mysoline) 
Propoxyphene (Darvon, 
Darvocet) 
Protriptyline (Vivactil) 
Quazepam (Doral) 
Ethosuximide (Zarontin) 
Felbamate (Felbatol) 
Fentanyl (Duragesic) 
Fluoxetine (Prozac) 
Fluphenazine (Permitil, Prolixin) 
Flurazepam (Dalmane) 
Fluvoxamine (Luvox) 
Gabapentin (Neurontin) 
Halazepam (Paxipam) 
Haloperidol (Haldol) 
Hydrocodone (Vicodin) 
Hydromorphone (Dilaudid) 
Imipramine (Tofranil) 
Isocarboxazid (Marplan) 
Levetiracetam (Keppra) 
Levorphanol (Levo-Dromoran) 
Lorazepam (Ativan)  
Loxapine (Loxitane, Loxitane C) 
Maprotiline (Ludiomil) 
Mephobarbital 
Meprobamate (Miltown, 
Equanil) 
Mesoridazine (Serentil) 
Methadone (Dolophine) 
Methsuximide (Celontin) 
Mirtazapine (Remeron) 
Molindone (Moban) 
Morphine (MS Contin) 
Nefazodone (Serzone) 
Quetiapine (Seroquel) 
Risperidone (Risperdal) 
Secobarbital (Seconal) 
Sertraline (Zoloft) 
Temazepam (Restoril)  
Thioridazine (Mellaril) 
Thiothixene (Navane) 
Tiagabine (Gabatril) 
Topiramate (Topamax) 
Tranylcypromine (Parnate) 
Trazodone (Desyrel) 
Triazolam (Halcion)  
Trifluoroperazine (Stelazine) 
Trimipramine (Surmontil) 
Venlafaxine (Effexor, Effexor 
XR) 
Ziprasidone (Geodon) 
Zolpidem (Ambien)  
Zonisamide (Zonegran) 
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